

CURRICULUM VITAE

Jared Murray Baeten, MD, PhD
Vice Chair, Department of Global Health
Professor, Departments of Global Health, Medicine, and Epidemiology
University of Washington

1. Personal Data

Mailing Address: International Clinical Research Center
Department of Global Health
University of Washington
Box 359927
325 Ninth Ave
Seattle, WA 98104

Office Address: International Clinical Research Center
Department of Global Health
University of Washington
Ninth and Jefferson Building
908 Jefferson, 12th floor, Room 1241
Seattle, WA 98104

Phone: +1-206-520-3808

Fax: +1-206-520-3831

Email: jbaeten@uw.edu

Birthdate: June 20, 1973

Birthplace: Green Bay, Wisconsin

Citizenship: U.S.A.

2. Education

May 1995 B.A., Chemistry, *summa cum laude*, Washington University, St. Louis, MO
B.A., Religious Studies, Washington University, St. Louis, MO

Aug 2001 Ph.D., Epidemiology, University of Washington, Seattle, WA
Dissertation: Prevention of HIV-1 shedding in women: trial of vitamin A
Advisor: Joan K. Kreiss, MD, MSPH

Jun 2003 M.D., with High Honors, University of Washington, Seattle, WA

3. Postgraduate Training

Jun 2003 – Jun 2006 Internship and Residency in Primary Care Internal Medicine
Massachusetts General Hospital, Boston, MA

Jul 2006 – Jun 2008 Fellowship in Infectious Diseases
University of Washington, Seattle, WA

4. Faculty Positions Held

Jul 2008 – Jun 2011	Assistant Professor Department of Global Health (primary) Department of Medicine, Division of Allergy and Infectious Diseases (joint) Adjunct Assistant Professor Department of Epidemiology University of Washington, Seattle, WA
Jul 2011 – Jun 2014	Associate Professor Department of Global Health (primary) Department of Medicine, Division of Allergy and Infectious Diseases (joint) Adjunct Associate Professor Department of Epidemiology University of Washington, Seattle, WA
Jul 2014 – present	Professor, with tenure Department of Global Health (primary) Department of Medicine, Division of Allergy and Infectious Diseases (joint) Department of Epidemiology (joint) University of Washington, Seattle, WA

5. Hospital Positions Held

2008 – present	Attending Physician, Department of Medicine, Division of Infectious Diseases Harborview Medical Center, Seattle, WA
2008 – present	Attending Physician, Department of Medicine, Division of Infectious Diseases University of Washington Medical Center, Seattle, WA

6. Honors

1994	Sigma Xi, Washington University
1995	Phi Beta Kappa, Washington University
1995	Sowden Prize, Department of Chemistry, Washington University
1997	Lange Award (for outstanding second year medical student)
2001	Outstanding Student Award, Department of Epidemiology, University of Washington
2002	Alpha Omega Alpha, University of Washington
2010	American Sexually Transmitted Diseases Association Young Investigator Award
2011	<i>Time Magazine</i> Top 10 Medical Breakthroughs of 2011
2012	University of Washington Science in Medicine Lecturer
2012	<i>POZ Magazine</i> 100 Leaders in HIV
2013	Outstanding Mentor Award, University of Washington School of Public Health
2013	Young Investigator's Award for Distinguished Research in Public Health, Association of Schools & Programs of Public Health
2014	Fellow, Infectious Diseases Society of America
2015	University of Washington School of Medicine Alumni Association Early Achievement Award

7. Board Certification

Internal Medicine 08/28/06, valid through 12/31/16

Infectious Diseases 10/06/08, valid through 12/31/18

8. Current Licensure

State of Washington License # MD00046319 Expiring 06/20/17

Federal DEA Expiring 07/31/17

9. Professional Organizations

- American College of Physicians
- American Sexually Transmitted Disease Association
- Infectious Disease Society of America (Fellow)
- International AIDS Society
- Western Society for Clinical Investigation

10. Teaching Responsibilities and Patient Care

Course Director

HIV/STI Prevention Research Methods (GH 563 / EPI 549)

- Spring 2010-2015
- Graduate-level course (3 credits, 3 hours of direct contact time per week) focusing on current research and implementation of HIV/STI prevention (biomedical, behavioral, and public health interventions). Includes analyzing strength of research evidence to support candidate interviews, understanding key features of clinical trial design, and applying appropriate/feasible interventions for specific settings and populations.
- ~20 students per year
- 75% responsibility 2010-2014 (with Connie Celum 2010-2013; with Renee Heffron 2014)
25% responsibility 2015 (with Renee Heffron)

Course Lecturer

1. Clinical Management of HIV and STDs (CONJ 553 / GH 573).
 - HIV testing and the initial evaluation of the HIV-infected patient: international perspective. (Winter 2007-2011)
 - Pre-exposure prophylaxis for HIV prevention. (Winter 2012-2014)
 - Pre-exposure prophylaxis and antiretroviral treatment for HIV prevention. (Spring 2015)
2. AIDS and STDs in Women and Children (OBGYN/EPI 590).
 - Genital herpes. (Spring 2007-2013)
 - Contraception and HIV risk. (Spring 2012)
3. AIDS: A Multidisciplinary Approach (EPI 530).
 - HIV prevention interventions. (Autumn 2010-2015)

4. Sociobehavioral & Prevention Research Methods for HIV & STI (EPI549/NMETH515).
 - New biomedical strategies for HIV prevention. (Spring 2008)
5. Principles of STD/HIV (UCONJ 555).
 - Integrating the laboratory into epidemiologic studies of HIV. (Summer 2007)
 - Journal club. (Summer 2011)
 - Pre-exposure prophylaxis (PrEP) for HIV prevention. (Summer 2008-2015)
 - Writing for medical journals. (Summer 2015)
6. Nairobi Principles of HIV Research.
 - Defining the question: use of observational data. (January 2009)
7. Epidemiology of Infectious Diseases in Resource-Limited Settings (EPI 532).
 - HIV epidemiology and prevention. (Summer 2009, Spring 2011, Spring 2013)
8. Epidemiologic Methods II (EPI 513).
 - Antiretroviral pre-exposure prophylaxis for HIV-1 prevention: a randomized, double-blind, placebo-controlled trial (practical aspects of conduct of a randomized trial). (Winter 2013-2015)
9. Intensive Course on Implementation Science for Family Planning and Reproductive Health.
 - Case study: Antiretroviral pre-exposure prophylaxis (PrEP) for HIV-1 prevention: from clinical trials to implementation. (Summer 2015)
10. STDs (EPI 220).
 - Biomedical HIV prevention: pre-exposure prophylaxis (PrEP). (Autumn 2015)

Graduate committees

Name	Degree	Field of Study	Role	Period
Jonathan Sugimoto	PhD	Epidemiology	Committee member (Graduate School Representative)	2009-2010
Linnet Masese, MPH	PhD	Epidemiology	Committee member	2009-2014
Renee Heffron, MPH	PhD	Epidemiology	Committee chair	2010-2012
Erin Kahle, MPH	PhD	Epidemiology	Committee chair	2010-2013
Elizabeth Irungu, MBChB	MPH	Epidemiology	Committee chair	2010-2012
Justin Brantley	MS	Epidemiology	Committee chair	2010-2014
Jennifer Carroll	PhD	Anthropology	Committee member (Graduate School Representative)	2011-2015
Kathryn Curran, MHS	PhD	Epidemiology	Committee chair	2011-2013
Pamela Murnane, MPH	PhD	Epidemiology	Committee chair	2012-2014
Andrew Mujugira, MBChB, MSc	MPH	Epidemiology	Committee chair	2012-2013
Kenneth Mugwanya, MBChB, MS	PhD	Epidemiology	Committee chair	2012-
Cameron Ball	PhD	Bioengineering	Committee member (Graduate School Representative)	2013-2014
Brett Hanscom	PhD	Biostatistics	Committee member (Graduate School Representative)	2013-2014
Yates Coley	PhD	Biostatistics	Committee member (Graduate School Representative)	2013-2014
Samuel Jenness, MPH	PhD	Epidemiology	Committee member	2013-2015
Jillian Pintye	MPH	Epidemiology	Committee chair	2013-2014
Marita Mann, MPH	PhD	Pharmacy	Committee member	2014-
Sarah Roberts, MPH	PhD	Epidemiology	Committee member	2014-

Name	Degree	Field of Study	Role	Period
Andrew Mujugira, MBChB, MPH	PhD	Epidemiology	Committee chair	2014-
Njambi Njuguna, MBChB	MPH	Global Health	Committee member	2014-
Jennifer Carroll, PhD	MPH	Epidemiology	Committee chair	2015-
Marla Husnik, MS	PhD	Epidemiology	Committee chair	2015-
Aaron Bochner, MPH	PhD	Epidemiology	Committee member	2015-
Kerry Thomson, MPH	PhD	Epidemiology	Committee member	2015-

Capstone project mentor

Student Name	Type	Project Name	Period
Hamid Idrees, MBChB	MPH student	Peer education for female sex workers	2011
Neway Feda, MBChB	MPH student	Antiretroviral resistance in Africa	2012

Trainees

Past / Current	Trainee Name (Training Details)	Pre / Post	Period	Prior Degree(s)	Prior Degree Years	Prior Degree Institution(s)	Title of Research Project	Current Position
Past	Kenneth Mugwanga (MS Epidemiology, Case Western Reserve, 2009)	Post	2007-2009	MBChB	2001	Makerere University	Knowledge and attitudes in HIV-1 serodiscordant couples in Uganda re: male circumcision for HIV-1 prevention	PhD student, UW
Past	Alison Silvis (Summer research project, UW)	Pre	2008	BA	2005	Stanford University	Correlates of <i>Trichomonas vaginalis</i> infection among HIV-1 serodiscordant couples	MD, PhD student
Past	Renee Heffron (PhD Epidemiology student, UW)	Pre	2008-2012	MPH	2004	Tulane University	Contraception, fertility and HIV-1 risk among HIV-1 serodiscordant couples	Post-doc, UW
Past	Justin Brantley (MS Epidemiology student, UW)	Pre	2008-2014	BA	2002	University of Texas	Adherence to PrEP	Data Manager/Analyst, UW
Past	Erin Kahle (PhD Epidemiology student, UW)	Pre	2008-2013	MPH	2002	University of Kansas	Risk factors for HIV-1 infectiousness	Assistant Professor, University of Michigan
Past	Shevin Jacob (infectious diseases fellow, UW)	Post	2008-2011	MD MPH	2004 2003	OHSU Harvard University	Sepsis interventions	Junior faculty, UW
Past	Kathryn Curran (PhD Epidemiology student, UW)	Pre	2009-2013	MHS	2007	Johns Hopkins University	Behavioral HIV-1 risks among HIV-1 serodiscordant couples	EIS officer, CDC
Past	Kenneth Ngure (visiting researcher, UW IARTP)	Pre	2009-2010	MPH	2006	University of Nairobi	Contraceptive and condom use behavioral among Kenyan HIV-1 serodiscordant couples	Lecturer, Jomo Kenyatta University
Past	Andrew Mujugira (visiting researcher, UW IARTP)	Post	2009	MBChB	2000	Makerere University	Comparison of Focus EIA and Western blot for serologic diagnosis of HSV-2	PhD student, UW
Past	Linnet Masese (PhD Epidemiology student, UW)	Post	2009-2014	MBChB MPH	2003 2008	University of Nairobi University of Washington	Epidemiologic linkages between Sex Transm Infect.	Researcher, Kenya
Past	Elizabeth Irungu (MPH Epidemiology student, UW)	Post	2010-2012	MBChB	2004	University of Nairobi	Immune response to HBV vaccination among HIV infected and uninfected adults	Researcher, Kenya

Past / Current	Trainee Name (Training Details)	Pre / Post	Period	Prior Degree(s)	Prior Degree Years	Prior Degree Institution(s)	Title of Research Project	Current Position
Past	Ruanne Barnabas (Postdoctoral fellow, UW)	Post	2010-2012	MBBS, MSc, DPhil	1997, 2000, 2005	U Cape Town, Oxford, Oxford	in Kenya Home-based HIV testing in South Africa	Assistant Professor, UW
Past	Pamela Murnane (PhD Epidemiology student, UW)	Pre	2010-2014	MPH	2008	Columbia University	Biologic and behavioral factors influencing PrEP effectiveness	Post-doctoral research associate, Columbia University
Past	Andrew Mujugira (MPH Epidemiology student, UW)	Post	2011-2013	MBChB	2000	Makerere University	Barriers to Antiretroviral Therapy Initiation Among HIV-1 Infected Individuals in East Africa	PhD candidate, UW
Past	Dennis Bii (visiting researcher, UW IARTP)	Post	2011	MBChB	2006	Moi University	Tenofovir pharmacokinetics in male genital mucosa	Research physician, Kenya
Current	Lynn Matthews (K23 MH095655 mentor committee)	Post	2011-present	MD MPH	2002 2011	University of Miami Harvard University	Periconception risk reduction for HIV discordant couples	Instructor, Harvard Medical School
Current	Renee Heffron (post-doctoral research associate, UW, K99 HD 076679 primary mentor)	Post	2012-present	PhD	2012	University of Washington	Antiretrovirals for HIV-1 prevention, periconception risk-reduction	Assistant Professor, UW
Current	Kenneth Mugwanga (PhD Epidemiology student, UW)	Post	2011-present	MBChB MS	2001 2009	Makerere University Case Western Reserve University	Working through challenges to implementing PrEP	PhD candidate, UW
Current	Sarah Roberts (PhD Epidemiology student, UW)	Pre	2012-present	MPH	2005	Emory	PrEP, sexual behavior, contraception, STIs	PhD student, UW
Current	Andrew Mujugira (PhD Epidemiology student, UW)	Post	2013-present	MBChB MPH	2000 2013	Makerere University University of Washington	Making antiretroviral therapy for HIV prevention deliverable	PhD candidate, UW
Past	Jillian Pintye (MPH Epidemiology student, UW)	Pre	2013-2014	BSN	2007	La Salle University	Male circumcision and syphilis acquisition and transmission	PhD student, UW School of Nursing
Current	Kerry Thomson (PhD Epidemiology student, UW)	Pre	2013-present	MPH	2007	Emory University	Pending	PhD student, UW
Current	Ingrid Katz (K23 MH097667 mentor committee)	Post	2014-present	MD	2004	Columbia University	Antiretroviral treatment refusal	Assistant Professor, Harvard Medical School
Current	Marla Husnik (PhD Epidemiology student, UW)	Pre	2014-present	MS	2004	University of Minnesota	Adherence to dapivirine vaginal ring for HIV-1 prevention	PhD student, UW
Current	Maria Pyra (PhD Epidemiology student, UW)	Pre	2014-present	MPH	2012	University of Illinois at Chicago	Pending	PhD student, UW
Current	Njambi Njuguna (MPH Epidemiology student, UW)	Pre	2014-present	MBChB MSPH	2005 2012	University of Nairobi Jomo Kenyatta University	SMS and HIV testing in Kenya	MPH student, UW
Current	Jennifer Balkus (UW CFAR New Investigator Award)	Post	2014-present	PhD	2012	University of Washington	HIV risk score in South African women	Staff scientist, FHCRC
Current	Zachary Kwena (UW CFAR Mentored	Post	2015-present	PhD	2014	Kenyatta University	Behavioral interventions for couples	Social scientist, Kenya Medical Research Institute

Past / Current	Trainee Name (Training Details)	Pre / Post	Period	Prior Degree(s)	Prior Degree Years	Prior Degree Institution(s)	Title of Research Project	Current Position
	International Award)							
Current	Paul Drain	Post	2015-present	MD	2007	University of Washington	Global TB, diagnostics, HIV-TB interactions	Assistant Professor, UW
	(K23 AI108293 mentor committee)			MPH	2001	University of Washington		
Current	Rena Patel	Post	2015-present	MD	2009	Stanford	Contraception and HIV treatment	Acting Instructor, UW
	(K23 AI120855 mentor)			MPH	2008	Harvard		
Current	Jennifer Velloza	Pre	2015-present				Pending	PhD student, UW
Current	Katherine Peebles	Pre	2015-present					PhD student, UW

Clinical attending

Harborview Medical Center – inpatient attending 4-6 weeks / year

Inpatient Internal Medicine (2 weeks)

- January 2010, January 2011, January 2012, May 2013, January 2014, January 2015
- Daily patient care supervisory responsibility and teaching with a total of ~6-8 resident physicians and 2-4 medical students per 2-week block.

Inpatient Infectious Diseases Consult Service (2 weeks)

- April 2011, April 2012
- Daily patient care supervisory responsibility and teaching with a total of 2-3 Infectious Diseases fellows, 1-2 resident physicians, and 2-4 medical students per 2-week block.

Inpatient HIV Consult Service (2 weeks)

- May 2012, January 2013, August 2013, April 2015
- Daily patient care supervisory responsibility and teaching with a total of 1-2 Infectious Diseases fellows per 2-week block.

Madison Clinic, Harborview Medical Center – as needed supervising attending with teaching of 1-2 resident physicians and 1-3 Infectious Diseases fellows per session. Generally 1-2 sessions per quarter.

Additional patient care

Madison Clinic, Harborview Medical Center – one half day per week of HIV primary care

11. Editorial Responsibilities

2008-2011; 2012-2015	Editorial Board member, <i>AIDS</i>
2013	Co-Editor, special issue on Family Planning and HIV, <i>AIDS</i>
2012 - present	Editorial Board member, <i>AIDS & Behavior</i>
2015	Co-Editor, special issue on The PrEP Revolution, <i>Current Opinion in HIV/AIDS</i>
2015 - present	Section Co-Editor (The Science of Prevention), <i>Current HIV/AIDS Reports</i>

12. Special National and International Responsibilities

National Institutes of Health Study Sections:

Standing study section

2015-2019 AIDS Clinical Studies and Epidemiology

Special emphasis panels / single episodes of reviewing

2011 NIH/PEPFAR Collaboration for Implementation Science and Impact Evaluation [ZAI1 BP-A J2 1]
2013 NIAID Investigator Initiated Program Project Applications [ZAI1 EWS-A (M1) 1]
2014 NIGMS SCORE program [ZGM1 TWD-8 (SC)]
2014 AIDS Clinical Studies and Epidemiology
2015 Implementation Science in HIV/AIDS Interventions [ZRG1 AARR-F (90) S]

Other grant reviews:

2009 - present Bill & Melinda Gates Foundation, multiple grants
2014 Wellcome Trust
2014 Medical Research Council of South Africa
2015 California HIV/AIDS Research Program
2015 UNITAID

Manuscript reviewer for the following journals (selection):

AIDS, Am J Obstet Gynecol, Clin Infect Dis, JAMA, J Acquir Immune Defic Syndr, J Infect Dis, Lancet, Lancet HIV, Lancet Infect Dis, PLoS Med, PNAS

Conference abstract reviewer

IAS 2011, ISSTD 2011, IAS 2012, ISSTD 2013, IAS 2013, IAS 2014, R4P 2014

2012 - present World Health Organization Task Force on Hormonal Contraception and HIV
2012 - present Microbicides Trials Network Contraception Steering Committee
2013 - present Microbicides Trials Network MTN-017 Study Monitoring Committee
2012 - present HIV Prevention Trials Network Combination Interventions Working Group
Jun 2013 Meeting co-chair, Long-acting Agents for HIV Treatment and Prevention: State of the Science and Implications for Adherence. Organized by NIH/NIAID. Miami, Florida.
2015-2018 Planned Parenthood Foundation of America, National Medical Committee
2015 NIH, Office of AIDS Research FY2017 Microbicides Planning Group
2015 - present World Health Organization Technical Working Group on PrEP
2015 - present PEPFAR Expert Working Group on PrEP

13. Special Local Responsibilities

1996-2003 Member, University of Washington School of Medicine Admissions Committee
2008, 2009, 2013 Grant reviewer, University of Washington Center for AIDS Research
2009, 2010 Grant reviewer, University of Washington Royalty Research Fund

2011-2013	Convener, University of Washington Center for AIDS Research seminar series
2012-2014	Deputy Director of Clinical Research (administrative position) International Clinical Research Center, Department of Global Health University of Washington
2012 – present	Member, University of Washington Department of Global Health Appointments and Promotions Committee
2014 – present	Member, University of Washington Department of Medicine Appointments and Promotions Committee
2014 – present	Member, PATH Research Ethics Committee
2014 – present	Co-Director (administrative position) International Clinical Research Center, Department of Global Health University of Washington
2015 – present	Vice Chair Department of Global Health, University of Washington

14. Research Funding

Time period	Funding Details	Total award direct costs
<u>CURRENT</u>		
07/01/07-12/31/16	Bill and Melinda Gates Foundation OOP47674 Pre-Exposure prophylaxis trial: antiretroviral drugs for HIV-uninfected partner to prevent HIV transmission among HIV-discordant couples (PI: C Celum) The goal of this project is to conduct a multi-site randomized trial in Africa to assess the efficacy of Tenofovir & Emtricitabine/tenofovir treatment on the sexual transmission of HIV in HIV-serodiscordant couples. <i>Role: Protocol Co-Chair and Medical Director</i>	\$65,060,954
08/10/11-05/31/16	NIH/NIMH R01 MH095507 Optimizing antiretroviral based HIV prevention for HIV serodiscordant couples (PI: J Baeten) We propose a series of integrated studies to optimize targeted delivery and sustained use of antiretroviral HIV-1 prevention in African HIV-1 serodiscordant couples. <i>Role: Principal Investigator</i>	\$2,255,076
09/01/12-12/31/16	Bill & Melinda Gates Foundation OPP1056051 An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples (The Partners PrEP Study Demonstration Project) (PI: J Baeten) This study proposes to test delivery of pre-exposure prophylaxis and antiretroviral therapy as an optimized, real-world demonstration among high-risk African HIV-1 serodiscordant couples. <i>Role: Principal Investigator</i>	\$2,919,137
07/13/12-07/12/16 (NCE)	USAID AID-OAA-A-12-00023 Evaluating antiretroviral (ARV)-based prevention in HIV-1 serodiscordant couples in Kenya and Uganda (PI: Celum) This proposal will provide critical information on targeted implementation, uptake, adherence, and cost-effectiveness of antiretroviral-based prevention which will inform how to implement these promising	\$2,373,654

Time period	Funding Details	Total award direct costs
04/01/12-03/31/16	interventions for African HIV-1 serodiscordant couples – a key population at high-risk of HIV-1 transmission – in a cost effective manner with maximum impact. <i>Role: Co-investigator / Project Co-Principal Investigator</i> NIH/NIAID R01 AI096968 PrEP and protective immune responses against HIV-1 (PIs: J Lund, J Baeten) We propose to explore anti-HIV-1 responses in HIV-1 exposed but uninfected persons receiving PrEP, evaluate the relationship between anti-HIV-1 immune responses and protection against HIV-1 acquisition and control of viral replication in breakthrough infections observed during prospective follow-up, and collect and test mucosal samples from persons on PrEP to evaluate immune responses at the site of HIV-1 exposure. <i>Role: Co-Principal Investigator</i>	\$2,355,191
06/10/13-06/30/15	Bill & Melinda Gates Foundation OPP996451 Planning and Preparing a Multi-Center, Open-Label, Randomized Clinical Trial of the Effect of Progestin-Only Contraception versus the Copper Intrauterine Device (IUD) on the Risk of HIV Acquisition in Young Women (PI: W Cates) This planning grant aims to design a randomized clinical trial of the effect of different widely available contraceptive types on risk of HIV acquisition. A multinational consortium will be established to conduct the trial. <i>Role: Co-investigator/Subcontract Principal Investigator</i>	\$610,106 (subcontract)
09/03/14-09/29/19	CDC U48 DP 005013 SIP 14-023 project (PIs: J Baeten, J Lingappa) Health Promotion and Disease Prevention Research Centers: Special Interest Project Competitive Supplements (SIPs) (PI: J Harris) The goal of the Health Promotion and Disease Prevention Research Centers is to design, test, and disseminate effective applied public health prevention research strategies to include behavioral interventions, environmental or system-wide solutions, and strategies that address major causes of disease and disability. SIP 14-023 is a Special Interest Project Supplement to the University of Washington Health Promotion Research Center. The project will conduct series of innovative clinical and biologic studies to understand the effect of progestin-based contraception on HIV-1 transmission and disease for this work, we will use our unique repository of data and biologic samples collected from women with and at-risk for HIV-1. <i>Role: Co-Principal Investigator (with J Lingappa)</i>	\$1,712,530 (project)
06/04/13-05/31/18	NIH/NIMH R01 MH098744 Real-world adherence to HIV PrEP in serodiscordant African couples (PI: J Haberer) The goal of this project is to determine if people can and will adhere adequately enough to PrEP in the “real world” to be protected against HIV seroconversion. <i>Role: Co-investigator/Subcontract Principal Investigator</i>	\$533,225 (subcontract)
08/01/14-05/31/17	NIH/NIDDK R01 DK100272 Incidence and implications of subclinical kidney injury with tenofovir based PrEP (PI: C Wyatt) The goal of the proposed research is to better understand the risk of kidney and bone toxicity with the use of TDF/FTC in healthy, HIV-uninfected individuals, and to leverage this unique opportunity to identify biomarkers of drug-induced kidney injury in the absence of chronic disease. <i>Role: Co-investigator/Subcontract Principal Investigator</i>	\$816,460 (subcontract)
09/30/10-08/31/15 (NCE)	NIH/NIAID RC4 AI092552 Interventions to decrease HIV infectiousness in Uganda (PI: C Celum)	\$4,300,727

Time period	Funding Details	Total award direct costs
11/13/13-03/31/17	This project will implement home-based HIV testing program in Uganda and South Africa to increase knowledge of HIV status with associated behavior change, and reduce HIV infectiousness through effective linkages to antiretroviral therapy and treatment of co-infections, and assessed by reduction in community viral load and transmission potential. <i>Role: Co-investigator</i> Bill & Melinda Gates Foundation OPP1095674 What are we doing right? What are we doing wrong? What are we not doing at all? Reimagining and reinvigorating HIV prevention for women at risk (PI: C Celum) This grant aims to bring together a multidisciplinary group to rethink HIV prevention in women. <i>Role: Co-Investigator</i>	\$1,010,761
04/01/15-03/31/19	NIH/NICCHD R01 HD083078 Design and delivery of combination HIV prevention in young South African women (PI: L Bekker) The purpose of this research is to conduct formative research about how women understand their risks and the role of social factors, which we hypothesize are central determinants of intention, motivation, adoption of and adherence to HIV prevention strategies. <i>Role: Co-Investigator</i>	\$154,903 (subcontract)
06/29/06-11/30/20	NIH/NIAID U01 AI068633 Microbicides Trial Network Core (PI: S Hillier; subcontract PI: C Celum) The mission of the MTN is to reduce the sexual transmission of HIV through the development and evaluation of products, which reduce the transmission of HIV when applied topically to mucosal surfaces. The goal is to conduct scientifically rigorous and ethically sound clinical trials of microbicide safety and effectiveness, which will support licensure of these products. <i>Role: Co-investigator and MTN-020/ASPIRE Protocol Chair</i>	\$5,768,137 (subcontract)
01/01/14-12/31/18	NIH/NIAID UM1 AI068615 Statistical and Data Management Center (SDMC): Microbicide Trials Network (PI: E Brown) The goal of the MTN is to conduct scientifically rigorous and ethically sound clinical trials of microbicide safety and effectiveness, which will support licensure of these products. The Statistical and Data Management Center is responsible for data management and analysis, including novel secondary analyses. The Epidemiology Core offers tremendous potential to perform cutting edge epidemiologic analyses of risk factors for HIV-1 and Sex Transm Infect. , using large databases collected as part of clinical trials of novel microbicides. <i>Role: Subcontract Principal Investigator</i>	\$153,735 (subcontract)
07/01/13-06/30/17	NIH/NICHD R01 HD077872 Effects of contraceptive ring on vaginal microbiota, HIV shedding and local immunity (PI: J Marrazzo) The goal is to study whether sustained vaginal delivery of estrogen promotes healthy vaginal populations of desirable vaginal bacteria (specific species of lactobacilli), and thus reduces risk of incident and persistent bacterial vaginosis (BV). <i>Role: Co-investigator</i>	\$1,670,215
08/01/13-05/31/15 (K period) 07/01/15-06/30/18 (R00 period)	NIH/NICH K99 (R00) HD076679 Antiretroviral periconception HIV prevention for HIV discordant couples (PI: R Heffron) This proposal outlines a 5-year career development plan and research strategy through which the Candidate will bolster her clinical epidemiology expertise with implementation and behavioral science research capacity and develop and pilot an intervention for HIV-1 risk reduction among	\$774,723 (during R years)

Time period	Funding Details	Total award direct costs
07/01/10-06/30/15	African HIV-1 serodiscordant couples desiring to conceive a child. <i>Role: Mentor</i> NIH/NIAID P01AI057005 Immunological and virological events in early HIV (PI: J Mullins, project (PI: J Lingappa) This project will assess virologic characteristics influencing HIV-1 transmission and early HIV-1 disease. <i>Role: Co-Investigator / Significant Contributor</i>	\$522,425 (project) \$1,466,328 (core)
09/01/13-06/30/17	NIH/NIMH R01 MH101027 Optimizing Delivery of ART/PrEP for HIV Prevention through Qualitative Research (PI: N Ware) This study proposes a qualitative evaluation of the bridging strategy, to inform future global implementation and scaleup of ART/PrEP for prevention in Africa. The project takes place in Kampala, Uganda. <i>Role: Co-Investigator / Significant Contributor</i>	No funds to University of Washington
03/03/14-02/28/18	NIH/NIAID R01 AI111738 Quantifying the impact of genital mucosal inflammation on HIV-1 acquisition risk (PI: J Lingappa) The major goal of this project is to use existing samples and data from African HIV-1 serodiscordant heterosexual couples (one partner HIV-1 infected and the other not) to quantify the most relevant mediators and test their power to predict HIV-1 infection. <i>Role: Significant Contributor</i>	\$1,770,671
<u>PENDING</u>		
07/01/15-09/30/20	Bill & Melinda Gates Foundation A Multi-Center, Open-Label, Randomized Clinical Trial of the Effect of Progestin-Only Contraception versus the Copper Intrauterine Device (IUD) on the Risk of HIV Acquisition in Young Women (PI: W Cates) This grant aims to conduct a randomized clinical trial of the effect of different widely available contraceptive types on risk of HIV acquisition. <i>Role: Co-investigator/Subcontract Principal Investigator</i>	\$5,971,553 (subcontract)
03/01/15-02/29/20	USAID APS-OAA-14-000076 Annual Program Statement for Microbicide Research, Development and Introduction, Round 3 Scalable, effective delivery of microbicides and PrEP for young women in Kenya and South Africa (co-PIs: C Celum, J Baeten) Objective 4: Develop cost-effective and scalable models for implementation of microbicides and other forms of PrEP for women through: a) identifying efficient and safe approaches for the provision of regular HIV-testing in programs offering microbicides and PrEP; b) working in partnership with women at high risk of HIV to design and implement microbicide adherence and retention support interventions integrated with other focused interventions to improve women's health and well-being. <i>Role: Co-Principal Investigator</i>	\$8,230,875
<u>COMPLETED</u>		
04/01/13-10/31/15 (NCE)	NIH/NICHD R21 HD074439 Hormonal contraception, pre-exposure prophylaxis, and HIV-1 protection (PI: J Baeten) This project will undertake epidemiologic analyses to understand the inter-relationships between contraceptive use, PrEP exposure, and HIV-1 acquisition and transmission risk, including assessment of biologic samples to explore misreporting of sexual behavior among women using and not using hormonal contraception. <i>Role: Principal Investigator</i>	\$275,000

Time period	Funding Details	Total award direct costs
09/01/95-02/28/15	NIH/NIAID R37 AI038518 Early infection in women exposed mucosally to HIV-1 (PI: J Overbaugh, subcontract PI: RS McClelland) The proposed research aims (1) to further define the relationship of viral complexity and viral subtype with systemic and mucosal viral burden and disease progression;(2) to determine if intersubtype recombinants are becoming more prevalent;(3) to determine if there are differences in neutralizing antibody responses in women who are initially infected with multiple variants versus a single variant;and (4) to examine the role of endogenous and exogenous female hormones in HIV shedding and pathogenesis during chronic disease. <i>Role: Significant Contributor</i>	\$400,327 (subcontract)
02/01/13-01/31/15	NIH/NIAID R21 AI104449 PrEP exposure during HIV-1 infection and the risk of low-frequency ARV resistance (PI: D Lehman) This study will use highly sensitive methods to detect antiretroviral resistance in high-risk Africans who became HIV infected while taking PrEP. <i>Role: Co-investigator/Subcontract Principal Investigator</i>	\$30,284 (subcontract)
09/01/09-06/30/14	NIH/NIAID/NICHD P01 HD064915 Mechanisms and co-Factors of HIV transmission to women (PI: J Overbaugh, project PI: RS McClelland) Project 2: Vaginal health and the risk of HIV-1 acquisition in Kenyan women This nested case-control study will compare vaginal flora among women who require HIV-1 versus those who remain HIV-negative. The findings will help to inform the development of a vaginal health approach to HIV-1 risk reduction in women. <i>Role: Significant Contributor</i>	\$400,741 (project)
04/01/09-03/31/14 (NCE)	NIH/NIAID R01 AI083034 Multicomponent, targeted HIV prevention for sub-Saharan Africa: preventionRx (PI: C Celum) This grant focuses on epidemiologic analyses and mathematical modeling to describe key determinants of HIV transmission in the generalized heterosexual epidemics in Africa. Pilot field work will be done to test the feasibility of combination HIV prevention interventions, in anticipation of designing an evidence-based HIV prevention package and a clinical trial of this prevention package. <i>Role: Project Director</i>	\$2,497,146
12/10/10-11/30/13 (NCE)	NIH/NINR R21 NR012663 Evaluation of antiretroviral HIV prevention in African HIV discordant couples (PI: J Baeten) To evaluate user preferences and risk-based targeting of ART-based HIV-1 prevention (PrEP and ART for HIV+ persons) among HIV-1 serodiscordant couples in Thika, Kenya. <i>Role: Principal Investigator</i>	\$275,288
08/01/11-07/31/13	NIH/NICHD R03 HD068143 Contraception, pregnancy, and HIV-1 risk in African HIV-1 serodiscordant couples (PI: J Baeten) The study will undertake epidemiologic analyses of the relationship between pregnancy and contraceptive use and HIV-1 acquisition and transmission risk using an existing dataset from a study of African HIV-1 serodiscordant couples. <i>Role: Principal Investigator</i>	\$100,000
08/01/09-07/15/13	Bill & Melinda Gates Foundation OOP52516 Adherence to Tenofovir and Truvada pre-exposure (PI: D Bangsberg) This study will explore adherence to antiretroviral pre-exposure prophylaxis within a clinical trial.	\$3,371,478 (subcontract)

Time period	Funding Details	Total award direct costs
09/17/10-03/31/13	<i>Role: Co-investigator</i> NIH/NIAID-PEPFAR R01 AI83034-S Multicomponent, targeted HIV prevention for sub-Saharan Africa: preventionRx (PI: C Celum) This supplement will assess whether home-based HIV counseling and testing (HBCT) achieves high uptake in KwaZulu Natal and is effective in achieving earlier identification of HIV-infected persons and active referrals to HIV care.	\$454,942
05/01/03-03/31/12	<i>Role: Project Director</i> Bill & Melinda Gates Foundation 26469 HSV-2 Suppression to Prevent HIV Transmission (PI: C Celum) Multi-site randomized phase III trial in Kenya and Uganda to assess the safety and efficacy of tenofovir & Emtricitabine/tenofovir treatment on the sexual transmission of HIV in HIV-serodiscordant couples.	\$62,121,367
09/01/10-06/30/11	<i>Role: Co-investigator</i> NIH/NIAID/NIMH R01 AI083034 Multi-component, Targeted HIV Prevention for Sub-Saharan Africa: PreventionRx, ARRA supplement (PI: C Celum) This supplement will focus on additional mathematical modeling of the population impact of CD4 and plasma viral load thresholds for ART initiation and on cost-effectiveness modeling.	\$511,689
09/01/98-05/31/13 Project: 07/01/09-06/30/11	<i>Role: Project Director</i> NIH/NIAID P30 AI027757 (University of Washington Center for AIDS Research New Investigator Award) HIV-1 Subtype Diversity: Implications for HIV-1 Transmission and Prevention (PI: K Holmes) This study will assess the relationship between HIV-1 subtype and heterosexual transmission risk, genital HIV-1 viral shedding, and early HIV-1 disease progression.	\$171,468 (subaward)
09/01/98-05/31/13 Project: 07/01/09-06/30/10	<i>Role: Principal Investigator</i> NIH/NIAID P30 AI027757 (University of Washington Center for AIDS Research Emerging Opportunities Award) Improving Adherence in an HIV Prevention Trial: A Pilot Intervention (PI: K Holmes) Pilot study to assess adherence to antiretroviral pre-exposure prophylaxis within a randomized clinical trial.	\$19,970
07/01/07-05/31/10	<i>Role: Principal Investigator</i> Bill and Melinda Gates Foundation 41185 Immune correlates of HIV protection (PI : MJ McElrath, subcontract PI: J Lingappa) This multicomponent project uses non-human primate studies to identify immunologic correlates of protection from SIV and applies findings to a cohort of African HIV discordant couples to evaluate these as immune correlates of protection against HIV.	\$1,979,827 (subcontract)
07/01/08-12/31/09	<i>Role: Co-investigator</i> Puget Sound Partners for Global Health HSV-2 infection, immune activation, and plasma and genital HIV-1 replication (PI: J Baeten) This project will assess the effect of HSV suppressive therapy on plasma and endocervical cytokine levels among HSV/HIV co-infected women.	\$74,778
	<i>Role: Principal Investigator</i>	

15. Bibliography

a. Peer-reviewed Publications

1. Smith CA, **Baeten J**, Taylor JS. The ability of a variety of polymerases to synthesize past site-specific *cis-syn*, *trans-syn*-II, (6-4), and Dewar photoproducts of thymidyl-(3'→5')-thymidine. *J Biol Chem*. 1998;273:21933-40.
2. **Baeten JM**, Richardson BA, Martin HL Jr, Nyange PM, Lavreys L, Ngugi EN, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. *J Acquir Immune Defic Syndr*. 2000;24:458-64.
3. **Baeten JM**, Bukusi EA, Lambe M. Pregnancy complications and outcomes among overweight and obese nulliparous women. *Am J Public Health*. 2001;91:436-40. PMID: 1446581.
4. **Baeten JM**, Mostad SB, Hughes MP, Overbaugh J, Bankson DD, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Selenium deficiency is associated with shedding of HIV-1 infected cells in the female genital tract. *J Acquir Immune Defic Syndr*. 2001;26:360-4.
5. **Baeten JM**, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, Jr., Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. *Am J Obstet Gynecol*. 2001;185:380-5.
6. **Baeten JM**, McClelland RS, Overbaugh J, Richardson BA, Emery S, Lavreys L, Mandaliya K, Bankson DD, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. *J Infect Dis*. 2002;185:1187-91.
7. Lavreys L, **Baeten JM**, Overbaugh J, Panteleeff DD, Chohan BH, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK. Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. *Clin Infect Dis*. 2002;35:77-81.
8. **Baeten JM**, McClelland RS, Richardson BA, Bankson DD, Lavreys L, Wener MH, Overbaugh J, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Vitamin A deficiency and the acute phase response among HIV-1 infected and uninfected women in Kenya. *J Acquir Immune Defic Syndr*. 2002;31:243-9.
9. **Baeten JM**, Chohan BH, Lavreys L, Rakwar JP, Ashley R, Richardson BA, Mandaliya K, Bwayo JJ, Kreiss JK. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. *AIDS*. 2002;16:2073-8.
10. **Baeten JM**, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. *Curr HIV Res*. 2003;1:69-86 [review].
11. Sagar M, Lavreys L, **Baeten JM**, Richardson BA, Mandaliya K, Chohan BH, Kreiss JK, Overbaugh J. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. *J Virol*. 2003;77:12921-6. PMID: 262567.
12. Lavreys L, **Baeten JM**, Kreiss JK, Richardson BA, Chohan BH, Panteleeff DD, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Injectable contraceptive use and genital ulcer disease during early human immunodeficiency virus type 1 (HIV-1) infection increase plasma virus load among women. *J Infect Dis*. 2004;189:303-11.
13. **Baeten JM**, Richardson BA, Bankson DD, Wener MH, Kreiss JK, Lavreys L, Mandaliya K, Bwayo JJ, McClelland RS. Use of serum retinol binding protein for prediction of vitamin A deficiency: effects of HIV-1 infection, protein malnutrition, and the acute phase response. *Am J Clin Nutr*. 2004;79:218-25.
14. Sagar M, Lavreys L, **Baeten JM**, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK, Overbaugh J. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. *AIDS*. 2004;18:615-9.

15. Lavreys L, **Baeten JM**, Martin HL, Jr., Overbaugh J, Mandaliya K, Ndinya-Achola J, Kreiss JK. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. *AIDS*. 2004;18:695-7.
16. **Baeten JM**, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, Wald A, Mandaliya K, Bwayo JJ, Kreiss JK. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. *J Infect Dis*. 2004;189:1466-71.
17. Lavreys L, Chohan V, Overbaugh J, Hasan W, McClelland RS, Kreiss JK, Mandaliya K, Ndinya-Achola J, **Baeten JM**. Hormonal contraception and risk of cervical infections among HIV-1- infected Kenyan women. *AIDS*. 2004;18:2179-84.
18. McClelland RS, **Baeten JM**, Overbaugh J, Richardson BA, Mandaliya K, Emery S, Lavreys L, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Multivitamin supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. *J Acquir Immune Defic Syndr*. 2004;37:1657-63.
19. McClelland RS, Lavreys L, Katingima C, Overbaugh J, Mandaliya K, Ndinya-Achola J, **Baeten JM**. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. *J Infect Dis*. 2005;191:333-8.
20. **Baeten JM**, Richardson BA, Lavreys L, Rakwar JP, Mandaliya KM, Bwayo JJ, Kreiss JK. Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men. *J Infect Dis*. 2005;191:546-53.
21. McClelland RS, Lavreys L, Hassan WM, Mandaliya K, Ndinya-Achola JO, **Baeten JM**. Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. *AIDS*. 2006;20:269-73.
22. Lavreys L, **Baeten JM**, Chohan V, McClelland RS, Hassan WM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Higher set point plasma viral load and more severe acute HIV-1 illness predict mortality among high-risk HIV-1 infected African women. *Clin Infect Dis*. 2006;42:1333-9.
23. McClelland RS, **Baeten JM**, Richardson BA, Lavreys L, Emery S, Mandaliya K, Ndinya-Achola JO, Overbaugh J. A comparison of genital HIV-1 shedding and sexual risk behavior among Kenyan women based on eligibility for initiation of HAART according to WHO guidelines. *J Acquir Immune Defic Syndr*. 2006;41:611-5.
24. **Baeten JM**, Wener MH, Bankson DD, Lavreys L, Richardson BA, Mandaliya K, Bwayo JJ, McClelland RS. HIV-1 infection alters the retinol-binding protein:transthyretin ratio even in the absence of the acute phase response. *J Nutr*. 2006;136:1624-9.
25. Drain PK, **Baeten JM**, Overbaugh J, Wener MH, Bankson DD, Lavreys L, Mandaliya K, Ndinya-Achola JO, McClelland RS. Low serum albumin and the acute phase response predict low serum selenium in HIV-1 infected women. *BMC Infect Dis*. 2006;6:85. PMID: 1479829.
26. McClelland RS, Hassan WM, Lavreys L, Richardson BA, Mandaliya K, Ndinya-Achola J, Jaoko W, Kurth AE, **Baeten JM**. HIV-1 acquisition and disease progression are associated with decreased high-risk sexual behaviour among Kenyan female sex workers. *AIDS*. 2006;20:1969-73.
27. Lavreys L, **Baeten JM**, Panteleeff DD, Richardson BA, McClelland RS, Chohan V, Mandaliya K, Ndinya-Achola JO, Overbaugh J. High levels of cervical HIV-1 RNA during early HIV-1 infection. *AIDS*. 2006;20:2389-90.
28. Benki S, McClelland RS, Emery S, **Baeten JM**, Richardson BA, Lavreys L, Mandaliya K, Overbaugh J. Quantitation of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. *J Clin Microbiol*. 2006;44:4357-62.

29. McClelland RS, Sangaré L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, Ndinya-Achola J, Jaoko W, **Baeten JM**. Infection with *Trichomonas vaginalis* increases the risk of HIV-1 acquisition. *J Infect Dis*. 2007;195:698-702.
30. **Baeten JM**, McClelland RS, Wener MH, Bankson DD, Lavreys L, Mandaliya K, Bwayo JJ, Kreiss JK. Relationship between markers of HIV-1 disease progression and serum beta-carotene concentrations in Kenyan women. *Int J STD AIDS*. 2007;18:202-6.
31. **Baeten JM**, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. *J Infect Dis*. 2007;195:1177-80.
32. Graham SM, **Baeten JM**, Richardson BA, Bankson DD, Lavreys L, Ndinya-Achola JO, Mandaliya K, Overbaugh J, McClelland RS. Higher pre-infection vitamin E levels are associated with higher mortality in HIV-1-infected Kenyan women: a prospective study. *BMC Infect Dis*. 2007;7:63. PMCID: 1914075.
33. **Baeten JM**, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. *Clin Infect Dis*. 2007;45:360-9 [review].
34. **Baeten JM**, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. *AIDS*. 2007;21:1771-7.
35. Graham SM, **Baeten JM**, Richardson BA, Wener MH, Lavreys L, Mandaliya K, Ndinya-Achola JO, Overbaugh J, McClelland RS. A decrease in albumin with HIV-1 seroconversion predicts subsequent disease progression. *AIDS Res Hum Retroviruses*. 2007;23:1197-200.
36. Manhart LE, Mostad SB, **Baeten JM**, Astete SG, Totten PA. High *Mycoplasma genitalium* organism burden is associated with shedding of HIV-1 DNA from the cervix. *J Infect Dis*. 2008;197:733– 6. PMCID: 4090222.
37. McClelland RS, Richardson BA, Hassan WM, Chohan, V, Lavreys L, Mandaliya K, Kiarie J, Jaoko W, Ndinya-Achola JO, **Baeten JM**, Kurth AE, Holmes KK. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. *J Infect Dis*. 2008;197:1361-8. PMCID: 4122228.
38. McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, Mandaliya K, Jaoko W, **Baeten JM**, Ndinya-Achola JO. A prospective study of risk factors for bacterial vaginosis in HIV-1 seronegative African women. *Sex Transm Dis*. 2008;35:617-23. PMCID: 3902781.
39. **Baeten JM**, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfecting women: a randomized, placebo-controlled, cross-over trial. *J Infect Dis*. 2008;198:1804-8. PMCID: 2665183.
40. Lingappa J, Kahle E, Mugo N, Mujugira A, Magaret A, **Baeten J**, Bukusi E, Cohen C, Katabira E, Ronald A, Kiarie J, Farquhar C, John-Stewart G, Makema J, Essex M, Were E, Fife K, deBruyn G, Gray G, McIntyre J, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayietnkore K, Karita E, Kanweka W, Delany S, Reese H, Vwalika B, Coombs R, Morrow R, Whittington W, Wald A, Corey L, Celum C; Partners in Prevention HSV-2/HIV-1 Transmission Study Team. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: The Partners Study. *PLoS One*. 2009;4:e5272. PMCID: 2671170.
41. McClelland RS, Richardson BA, Hassan WM, Graham SM, Kiarie J, **Baeten JM**, Mandaliya K, Jaoko W,

- Ndinya-Achola JO, Holmes KK. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. *J Infect Dis*. 2009;199:1883-90. PMID: 2743896.
42. Piantadosi A, Chohan B, Panteleeff D, **Baeten JM**, Mandaliya K, Ndinya-Achola JO, Overbaugh J. HIV-1 evolution in *gag* and *env* is highly correlated but exhibits different relationships with viral load and the immune response. *AIDS*. 2009;23:579-87. PMID: 2727980.
 43. Piantadosi A, Panteleeff D, Blish CA, **Baeten JM**, Jaoko W, McClelland RS, Overbaugh J. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. *J Virol*. 2009;83:10269-74. PMID: 2748011.
 44. **Baeten JM**, Hassan WM, Chohan V, Richardson BA, Mandaliya K, Ndinya-Achola JO, Jaoko W, McClelland RS. Prospective study of correlates of vaginal *Lactobacillus* colonisation among high-risk HIV-1 seronegative women. *Sex Transm Infect*. 2009;85:348-53. PMID: 2837477.
 45. Ngure K, Heffron R, Mugo N, Irungu E, Celum C, **Baeten JM**. Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial. *AIDS*. 2009;23:S89-95.
 46. Chohan V, **Baeten JM**, Benki S, Graham SM, Lavreys L, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J, McClelland RS. A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. *Sex Transm Infect*. 2009;85:489-92. PMID: 2813217.
 47. Graham SM, Masese L, Gitau R, Mwakangalu D, Jaoko W, Ndinya-Achola J, Mandaliya K, Peshu N, **Baeten JM**, McClelland RS. Increased risk of genital ulcer disease in women during the first month after initiating antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2009;52:600-3. PMID: 2787852.
 48. Celum C, Wald A, Lingappa JR, Magaret AS, Wang R, Mugo N, Mujugira A, **Baeten JM**, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WLH, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med*. 2010;362:427-39. PMID: 2838503.
 49. **Baeten JM**, Donnell D, Kapiga S, Ronald A, John-Stewart G, Inambao M, Manongi R, Vwalika B, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1 serodiscordant couples. *AIDS*. 2010;24:737-44. PMID: 2919808.
 50. Lingappa JR, **Baeten JM**, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, John-Stewart G, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre J, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret A, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners HSV-2/HIV-1 Transmission Study Team. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. *Lancet*. 2010;375:824-33. PMID: 2877592.
 51. Reid SE, Dai JY, Wang J, Sicalwe B, Akpomiemie G, Cowan F, Delany-Moretwe S, **Baeten JM**, Hughes J, Wald A, Celum C. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. *J Acquir Immune Defic Syndr*. 2010;53:606-13. PMID: 2845724.
 52. * Donnell D, **Baeten JM**, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C, for the Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet*. 2010;375: 2092-8.

53. Curlin ME, Huang M-L, Lu X, Celum CL, Sanchez J, Selke S, **Baeten JM**, Zuckerman RA, Erdman DD, Corey L. Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men. *PLoS One*. 2010;5:e11321. PMCID: 2892480.
54. Matthews LT, **Baeten JM**, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. *AIDS*. 2010;24:1975-82 [opinion/review]. PMCID: 3773599.
55. Heffron R, Were E, Celum C, Mugo N, Ngure K, Kiarie J, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. *Sex Transm Dis*. 2010;37:1-8.
56. Lingappa JR, Hughes JP, Wang RS, **Baeten JM**, Celum C, Gray GE, Stevens W, Donnell D, Campbell MS, Farquhar C, Essex M, Mullins JI, Coombs RW, Rees H, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. *PLoS One*. 2010;5:e12598. PMCID: 2938354.
57. Mugwanya KK, **Baeten JM**, Nakku-Joloba E, Katabira E, Celum C, Tisch D, Whalen CC. Knowledge and attitudes about male circumcision for HIV-1 prevention among heterosexual HIV-1 serodiscordant partnerships in Kampala, Uganda. *AIDS Behav*. 2010;14:1190-7. PMCID:4562410.
58. **Baeten JM**, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HSV-2/HIV-1 dually-infected persons. *J Infect Dis* 2011;203:117-21. PMCID: 3024584.
59. Sánchez J, Sal y Rosas VG, Hughes JP, **Baeten JM**, Fuchs J, Buchbinder S, Koblin BA, Casapia M, Ortiz A, Celum C. Male circumcision and risk of HIV acquisition among MSM. *AIDS*. 2011;25:519-23. PMCID: 307254.
60. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert JH, Hayes RJ, **Baeten JM**, Brown J, Delany-Moretlwe S, Kaul R, McGrath N, Morrison C, Myer L, Temmerman M, van der Straten A, Watson-Jones D, Zwahlen M, Hilber AM. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. *PLoS Med*. 2011;8:e1000416. PMCID: 3039685.
61. Hallett TB, Alsallaq RA, **Baeten JM**, Weiss H, Celum C, Gray R, Abu-Raddad L. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. *Sex Transm Infect*. 2011;87:88-93. PMCID: 3272710.
62. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, Sorensen S, Stoddard JN, Zhao H, Deng W, Kahle E, Panteleeff D, **Baeten JM**, McCutchan FE, Albert J, Leitner T, Wald A, Corey L, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. *PLoS One*. 2011;6:e16986. PMCID: 3047537.
63. Mujugira A, Magaret AS, **Baeten JM**, Celum C, Lingappa J. Risk factors for HSV-2 infection among sexual partners of HSV-2/HIV-1 co-infected persons. *BMC Res Notes*. 2011;4:64. PMCID: 3064615.
64. Blish CA, **Baeten JM**. Hormonal contraception and HIV-1 transmission. *Am J Reprod Immunol*. 2011;65:320-7 [review]. PMCID: 3058314.
65. Mujugira A, Morrow RA, Celum C, Lingappa J, Delany-Moretlwe S, Fife KH, Heffron R, De Bruyn G, Homawoo B, Karita E, Mugo N, Vwalika B, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries. *Sex Transm Infect*. 2011;87:238-41. PMCID:

66. * **Baeten JM**, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. *Sci Transl Med*. 2011;3:77ra29. PMID: 3087186.
67. Philpott S, Heise L, McGrory E, Paxton L, Hankins C; participants in the 2009 GCM/CDC/UNAIDS Consultation on Standards of Prevention in HIV Prevention Trials (included as consultation participant). The challenge of defining standards of prevention in HIV prevention trials. *J Med Ethics*. 2011;37:244-8.
68. Jacob ST, **Baeten JM**, Hughes J, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs J, Koblin B, Griffith S, Wald A, Celum C, for the HPTN 039 Protocol Team. A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. *AIDS Behav*. 2011;15:897-904. PMID: 3076532.
69. Mugwanya KK, Whalen C, Celum C, Nakku-Joloba E, Katabira E, **Baeten JM**. Circumcision of male children for reduction of future risk for HIV: acceptability among HIV serodiscordant couples in Kampala, Uganda. *PLoS One*. 2011;6:e22254. PMID: 3140501.
70. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, Celum C, Kiarie JN, Cohen CR, Kayintekore K, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. *AIDS* 2011;25:1887-95. PMID: 3173565.
71. Mujugira A, **Baeten JM**, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C; Partners PrEP Study Team. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. *PLoS One*. 2011;6:e25828. PMID: 3187805.
72. Were E, Curran K, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Kiarie J, Bukusi EA, Celum C, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. *AIDS*. 2011;25:2009-18. PMID: 3718250.
73. Hallett T, **Baeten JM**, Heffron R, Barnabas R, de Bruyn G, Cremin I, Delany S, Garnett GP, Gray G, Johnson L, McIntyre J, Rees H, Celum C. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. *PLoS Med*. 2011;8:e1001123. PMID: 3217021.
74. Mugwanya KK, **Baeten JM**, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfecting persons: a randomized, crossover trial. *J Infect Dis*. 2011;204:1912-7. PMID: 3247811.
75. Ndase P, Celum C, Thomas K, Donnell D, Fife KH, Bukusi E, Delany-Moretlwe S, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships. *J Acquir Immune Defic Syndr*. 2012;59:65-71. PMID: 3237862.
76. Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath MJ, Thomas K, **Baeten JM**, Celum C, Wald A, de Bruyn G, Mullins JI, Nakku-Joloba E, Farquhar C, Essex M, Donnell D, Kiarie J, Haynes B, Goldstein D; Partners in Prevention HSV/HIV Transmission Study Team. Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. *PLoS One*. 2011;6:e28632. PMID: 3236203.

77. **Baeten JM**, Reid SE, Delany-Moretlwe S, Hughes JP, Wang RS, Wilcox E, Limbada M, Akpomiemie G, Corey L, Wald A, Celum C. Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. *Sex Transm Dis.* 2012;39:21-4. PMID: 3244838.
78. * Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. *Lancet Infect Dis.* 2012;12:19-26. PMID: 3266951.
79. Hughes JP, **Baeten JM**, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. *J Infect Dis.* 2012;205:358-65. PMID: 3256946.
80. Ngure K, Heffron R, Mugo NR, Celum C, Cohen CR, Odoyo J, Rees H, Kiarie JN, Were E, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. *AIDS.* 2012; 26:513-8. PMID: 3932300.
81. Ware NC, Wyatt MA, Haberer JE, **Baeten JM**, Kintu A, Psaros C, Safren S, Tumwesigye E, Celum CL, Bangsberg DR. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. *J Acquir Immune Defic Syndr.* 2012;59:463-8. PMID: 3826169.
82. Ngure K, Mugo N, Celum C, **Baeten JM**, Morris M, Olungah O, Olenja J, Tamooch H, Shell-Duncan B. A qualitative study of barriers to consistent condom use among HIV-1 serodiscordant couples in Kenya. *AIDS Care.* 2012;24:509-16. PMID: 3932299.
83. Lu Y, Celum C, Wald A, **Baeten JM**, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L, Hendrix CW. Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. *Antimicrob Agents Chemother.* 2012;56:2777-9. PMID: 3346629.
84. Curran K, **Baeten JM**, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. *Curr HIV/AIDS Rep.* 2012;9:160-70 [review]. PMID: 3570050.
85. Jacob ST, Banura P, **Baeten JM**, Moore CC, Meya D, Nakiyingi L, Burke R, Horton CL, Boaz I, Wald A, Reynolds SJ, Mayanja-Kizza H, Scheld WM; Promoting Resource-Limited Interventions for Sepsis Management in Uganda (PRISM-U) Study Group. The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study. *Crit Care Med.* 2012;40:2050-8. PMID: 3378757.
86. Cohen CR, Lingappa JR, **Baeten JM**, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. *PLoS Med.* 2012;9:e1001251. PMID: 3383741.
87. * **Baeten JM**, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kania A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooch H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus N, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012;367:399-410. PMID: 3770474.

88. Holte SE, Randolph TW, Ding J, Tien J, McClelland RS, **Baeten JM**, Overbaugh J. Efficient use of longitudinal CD4 counts and viral load measures in survival analysis. *Stat Med*. 2012;31:2086-97. PMID: 3641845.
89. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, **Baeten JM**. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. *J Acquir Immune Defic Syndr*. 2012;61:116-9. PMID: 3427394.
90. Mackelprang RD, **Baeten JM**, Donnell D, Celum C, Farquhar C, de Bruyn G, Essex M, McElrath MJ, Nakku-Joloba, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team. Quantifying ongoing HIV-1 exposure in HIV-1 serodiscordant couples to identify individuals with potential natural host resistance to HIV-1. *J Infect Dis*. 2012;206:1299-308. PMID: 3448964.
91. de Bruyn G, Magaret A, **Baeten JM**, Lingappa J, Ndase P, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team. Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial. *BMC Infect Dis*. 2012;12:277. PMID: 3582549.
92. Blish CA, McClelland RS, Richardson BA, Jaoko W, Mandaliya K, **Baeten JM**, Overbaugh J. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. *J Acquir Immune Defic Syndr*. 2012;61:436-40. PMID: 3494808.
93. Murnane PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, Kiarie J, Wald A, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. *PLoS One*. 2012;7:e51192. PMID: 3511400.
94. Tumwebaze H, Tumwesigye E, **Baeten JM**, Kurth AE, Revall J, Murnane PM, Chang LW, Celum C. Household-based HIV counseling and testing as a platform for referral to HIV care and medical male circumcision in Uganda: a pilot evaluation. *PLoS One*. 2012;7:e51620. PMID: 3521653.
95. Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa JR, Celum C, **Baeten JM**, Campbell M, Essex M, De Bruyn G, Farquhar C, Quinn TC, Eshelman SH; Partners in Prevention HSV/HIV Transmission Study Team. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known non-recent HIV infection from five African countries. *AIDS Res Hum Retroviruses*. 2012;28:1177-8. PMID: 3448109.
96. Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, Rees H, Kiarie J, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Hormonal contraceptive use and risk of HIV-1 disease progression. *AIDS*. 2013;27:261-7. PMID: 3266951.
97. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, **Baeten JM**. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. *J Infect Dis*. 2013;207:402-10. PMID: 3537443.
98. Alsallaq R, **Baeten JM**, Celum C, Hughes J, Abu-Raddad LJ, Barnabas RV, Hallett TB. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. *PLoS One*. 2013;8:54575. PMID: 3553021.
99. Masese L, **Baeten JM**, Richardson BA, Deya R, Kabare E, Bukusi E, John-Stewart G, Jaoko W, McClelland RS. Incidence and correlates of *Chlamydia trachomatis* infection in a high-risk cohort of Kenyan women. *Sex Transm Dis*. 2013;40:221-5. PMID: 3831875.
100. Kahle E, Hughes J, Lingappa J, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. *J Acquir Immune Defic Syndr*. 2013;62:339-47. PMID: 2381875.

101. Campbell MS, Kahle EM, Celum C, Lingappa JR, Kapiga S, Mujugira A, Mugo NR, Fife KH, Mullins JI, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters. *J Infect Dis*. 2013;207:1166-70. PMID: 3583276.
102. Mujugira A, Heffron R, Celum C, Mugo N, Nakku-Joloba E, **Baeten JM**; Partners PrEP Study Team. Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships. *J Acquir Immune Defic Syndr*. 2013;63:e33-5. PMID: 3624622.
103. Perti T, Saracino M, **Baeten JM**, Johnston C, Diem K, Ochbamiichael N, Huang M-L, Selke S, Magaret A, Corey L, Wald A. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfectd with HIV-1 and HSV-2: a randomized, crossover trial. *J Acquir Immune Defic Syndr*. 2013;63:201-8. PMID: 3738066.
104. Donnell D, **Baeten JM**, Hong T, Lingappa JR, Mujugira A, Nakku-Joloba E, Bangsberg D, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence. *AIDS Behav*. 2013;17:632-9. PMID: 3721974.
105. Lingappa JR, Thomas KK, Hughes JP, **Baeten JM**, Farquhar C, de Bruyn G, Fife KH, Campbell MS, Kapiga S, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. *AIDS Res Hum Retroviruses*. 2013;29:164-71. PMID: 3537302.
106. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, **Baeten JM**; Partners PrEP Study Team. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. *AIDS*. 2013;27:2155-60. PMID: 3882910.
107. Jacob ST, Pavlinac P, Nakiyingi L, Banura P, **Baeten JM**, Morgan K, Magaret A, Manabe Y, Reynolds SJ, Liles WC, Wald A, Joloba ML, Mayanja-Kizza H, Scheld WM. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected patients hospitalized with severe sepsis in Uganda: high frequency, low clinical suspicion and derivation of a clinical prediction score. *PLoS One*. 2013;8:e70305. PMID: 3734073.
108. van Rooyen H, Barnabas RV, **Baeten JM**, Phakathi Z, Joseph P, Krows M, Hong T, Murnane PM, Hughes J, Celum C. High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal. *J Acquir Immune Defic Syndr*. 2013;64:e1-e8. PMID: 3744613.
109. Haberer JE, **Baeten JM**, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. *PLoS Med*. 2013;10:e1001511. PMID: 3769210.
110. Curran K, Mugo NR, Kurth A, Ngure K, Heffron R, Donnell D, Celum C, **Baeten JM**. Daily short message service surveys to measure sexual behavior and pre-exposure prophylaxis use among Kenyan men and women. *AIDS Behav*. 2013;17:2977-85. PMID: 3812384.
111. Baisley K, **Baeten JM**, Hughes JP, Donnell D, Wang J, Hayes R, Watson-Jones D, Celum C. Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reporting. *AIDS Behav*. 2013;17:3108-19. PMID: 3812335.
112. Pattacini L, Murnane PM, Kahle EM, Bolton MJ, Delrow JJ, Lingappa JR, Katabira E, Donnell D, McElrath

- MJ, **Baeten JM**, Lund JM. Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals. *AIDS Res Hum Retroviruses*. 2013;29:1321-9. PMID: 3785803.
113. Polis CB, Westreich D, Balkus JE, Heffron R; Participants of the 2013 HC-HIV Observational Analysis Meeting (included as a meeting participant). Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. *AIDS*. 2013;27 Suppl 1:S35-43.
 114. Mujugira A, Magaret AS, Celum C, Lingappa J, **Baeten JM**, Morrow RA, Fife KH, Delany-Moretlwe S, De Bruyn G, Bukusi E, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfecting persons: a randomized controlled trial. *J Infect Dis*. 2013;208:1366-74. PMID: 3789565.
 115. Barnabas R, Ying R, van Rooyen H, Murnane P, Hughes J, **Baeten J**, Celum C. Use of HIV viral-load suppression to estimate the effect of community-wide home-based HIV counselling and testing and linkage to antiretroviral therapy on HIV incidence in South Africa: a mathematical modelling analysis. *Lancet*. 2013;382:S6.
 116. Masese L, **Baeten JM**, Richardson BA, Bukusi E, John-Stewart G, Jaoko W, Shafi J, Estambale B, Kiarie J, McClelland RS. Incidence herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. *J Infect Dis*. 2014;209:1023-7. PMID: 3952675.
 117. Mugwanya K, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, Katabira E, Ngure K, **Baeten JM**; Partners PrEP Study Team. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention. *Lancet Infect Dis*. 2013;13:1021-8. PMID: 3920826.
 118. Curran K, Ngure K, Shell-Duncan B, Vusha S, Mugo NR, Heffron R, Celum C, **Baeten JM**. "If I am given antiretrovirals I will think I am nearing the grave": Kenyan HIV serodiscordant couples' attitudes regarding early initiation of antiretroviral therapy. *AIDS*. 2014;28:227-33. PMID: 4040408.
 119. Kahle E, Campbell M, Lingappa J, Donnell D, Celum C, Kapiga S, Ondondo R, Mugo N, Mujugira A, Fife K, Mullins J, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples. *AIDS*. 2014;28:235-43. PMID: 4090091.
 120. Kahle EM, Kashuba A, **Baeten JM**, Fife KH, Celum C, de Bruyn G, Mujugira A, Essex M, Wald A, Donnell D, John-Stewart G, Delany-Moetlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team. Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. *J Acquir Immune Defic Syndr*. 2014;65:e90-4. PMID: 3898592.
 121. Heffron R, Donnell D, Kiarie J, Rees H, Ngure K, Mugo N, Were E, Celum C, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naïve HIV-1-infected women. *J Acquir Immune Defic Syndr*. 2014;65:231-6. PMID: 3898601.
 122. Pattacini L, Murnane PM, Fluharty T, de Rosa SC, **Baeten JM**, Lund JM. Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells. *J Virol Methods*. 2014;199C:17-24. PMID: 3951839.
 123. Lehman DA, Ronen K, Blish CA, **Baeten JM**, Jalalian-Lechak Z, Jaoko W, Mandaliya K, Richardson BA, McClelland RS, Overbaugh J. Systemic cytokine levels show limited correlation with risk of HIV-1 acquisition. *J Acquir Immune Defic Syndr*. 2014;66:135-9. PMID: 4020985.
 124. Ndase P, Celum C, Campbell J, Bukusi E, Kiarie J, Katabira E, Mugo N, Tumwesigye E, Wangisi J, Were E, Brantley J, Donnell D, **Baeten JM**; Partners PrEP Study Team. Successful discontinuation of the

placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the Partners PrEP Study experience. *J Acquir Immune Defic Syndr.* 2014;66:206-12.

125. Celum C, Morrow R, Donnell D, Hong T, Hendrix CW, Thomas K, Fife K, Nakku-Joloba E, Mujugira A, **Baeten JM**; Partners PrEP Study Team. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. *Ann Intern Med.* 2014;161:11-9.
126. Donnell D, **Baeten JM**, Bumpus N, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C; Partners PrEP Study Team. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. *J Acquir Immune Defic Syndr.* 2014;66:340-8. PMID: 4059553.
127. Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, Bukusi E, Tumwesigye E, **Baeten JM**; Partners PrEP Study Team. Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. *J Acquir Immune Defic Syndr.* 2014;66:436-42. PMID: 4077929.
128. Psaros D, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, Wangisi J, Mugwanya K, Kintu A, Enyakoit M, Thomas KK, Donnell D, Krows M, Kidoguchi L, Ware N, **Baeten JM**, Celum C, Bangsberg DR, Safren SA. An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. *J Acquir Immune Defic Syndr.* 2014;66:522-9. PMID: 4191829.
129. Murnane P, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, Were E, Mujugira A, Kiaire J, Celum C, **Baeten JM**; Partners PrEP Study Team. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. *AIDS.* 2014;28:1825-30. PMID: 4136509.
130. Ngure K, **Baeten JM**, Mugo N, Curran K, Vusha S, Heffron R, Celum C, Shell-Duncan B. My intention was a child but I was very afraid: fertility intentions and HIV risk perception among HIV-serodiscordant couples experiencing pregnancy in Kenya. *AIDS Care.* 2014;26:1283-7. PMID: 4087054.
131. Osthoff M, Irungu E, Ngure K, Thomas KK, **Baeten JM**, Eisen DP. Mannose-binding lectin and ficolin-2 do not influence humoral immune response to hepatitis B vaccine. *Vaccine.* 2014;32:4772-7. PMID: 4374143.
132. * Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews L, Morrison S, Ngure K, **Baeten JM**; Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized, placebo-controlled trial. *JAMA.* 2014;312:362-71. PMID: 25038355.
133. Were EO, Heffron R, Mugo NR, Celum C, Mujugira A, Bukusi EA, **Baeten JM**; Partners PrEP Study Team. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. *AIDS.* 2014;28:1977-82. PMID: 4216472.
134. Roberts ST, Heffron R, Ngure K, Celum C, Kurth A, Curran K, Mugo N, **Baeten JM**. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. *AIDS Behav.* 2014;18:1701-11. PMID: 4127114.
135. Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, **Baeten JM**; Partners PrEP Study Team. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. *J Acquir Immune Defic Syndr.* 2014;67:91-7. PMID: 4149628.
136. Heffron R, Mugo N, Were E, Kiarie J, Bukusi EA, Mujugira A, Frenkel L, Donnell D, Ronald A, Celum C, **Baeten JM**; Partners PrEP Study Team. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. *AIDS.* 2014;28:2771-6.

137. Barnabas RV, van Rooyen H, Tumwesigye E, Murnane PM, **Baeten JM**, Humphries H, Turyamureeba B, Joseph P, Krows M, Hughes JP, Celum C. Initiation of antiretroviral therapy and viral suppression after home HIV testing and counselling in KwaZulu-Natal, South Africa, and Mbarara district, Uganda: a prospective, observational intervention study. *Lancet HIV*. 2014;1:e68-76. PMCID: 4292844.
138. Pintye J, **Baeten JM**, Manhart L, Celum C, Ronald A, Mugo N, Mujugira A, Cohen C, Were E, Bukusi E, Kiarie J, Heffron R; Partners PrEP Study Team. Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. *Lancet Glob Health*. 2014;2:664-71. PMCID: 4271270.
139. **Baeten JM**, Donnell D, Mugo N, Ndase P, Thomas K, Campbell J, Wangisi J, Tappero J, Bukusi E, Cohen C, Katabira E, Ronald A, Tumwesigye E, Were E, Fife K, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs R, Hendrix C, Marzinke M, Frenkel L, Haberer J, Bangsberg D, Celum C; Partners PrEP Study Team. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *Lancet Infect Dis*. 2014;14:1055-64. PMCID: 4252589.
140. Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, **Baeten JM**; Partners PrEP Study Team. Changes in glomerular kidney function among HIV-1 uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. *JAMA Int Med*. 2015;175:245-54. PMCID: 4354899.
141. Mackelprang RD, Carrington M, Thomas KK, Hughes J, **Baeten JM**, Wald A, Farquhar C, Fife K, Campbell MS, Kapiga S, Gao X, Mullins JI, Lingappa JR. Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-Saharan Africa. *J Virol*. 2015;89:2104-11. PMCID: 4338863.
142. Morrison CS, Chen P-L, Kwok C, **Baeten JM**, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Abdool Karim Q, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JHHM, Stalter R, Low N. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. *PLoS Med*. 2015;12:e1001778. PMCID: 4303292.
143. Jewell BL, Cremin Í, Pickles M, Celum C, **Baeten JM**, Delany-Moretlwe S, Hallett TB. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. *PLoS One*. 2015;10: e0115511. PMCID: 4304839.
144. Ware NC, Pisarski EE, Haberer JE, Wyatt MA, Tumwesigye E, **Baeten JM**, Celum CL, Bangsberg DR. Lay social resources for support of adherence to antiretroviral prophylaxis for HIV prevention among serodiscordant couples in sub-Saharan Africa: a qualitative study. *AIDS Behav*. 2015;19:811-20.
145. Lehman DA, **Baeten JM**, McCoy C, Weis J, Peterson D, Mbara G, Donnell D, Thomas K, Hendrix C, Frenkel L, Ndase P, Mugo N, Celum C, Overbaugh J, Matsen F; Partners PrEP Study Team. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. *J Infect Dis*. 2015;211:1211-8. PMCID: 4402339.
146. Smith JA, Sharma M, Levin C, **Baeten JM**, van Rooyen H, Celum C, Hallett TB, Barnabas RV. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. *Lancet HIV*. 2015;2:e159-e168. PMCID: 4384819.
147. Ndase P, Celum C, Kidoguchi L, Ronald A, Fife KH, Bukusi E, Donnell D, **Baeten JM**; Partners PrEP Study Team. Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions. *PLoS One*. 2015;10:e0123005. PMCID: 4401675.

148. Kahle EM, Bolton M, Hughes JP, Donnell D, Celum C, Lingappa JR, Ronald A, Cohen CR, de Bruyn G, Fong Y, Katabira E, McElrath MJ, **Baeten JM**; Partners in Prevention HSV/HIV Transmission Study Team. Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples. *J Infect Dis.* 2015;211:1451-60. PMID: 4447828.
149. Haberer JE, Bangsberg DR, **Baeten JM**, Curran K, Koechlin F, Amico KR, Anderson P, Mugo N, Venter F, Goicochea P, Caceres C, O'Reilly K. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. *AIDS.* 2015;29:1277-85. PMID: 4480436.
150. Noguchi LM, Richardson BA, **Baeten JM**, Hillier SL, Balkus JE, Chirenje ZM, Bunge K, Ramjee G, Nair G, Palanee-Phillips T, Selepe P, van der Straten A, Parikh UM, Gomez K, Piper JM, Watts HD, Marrazzo JM; VOICE Study Team. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. *Lancet HIV.* 2015;2:e279-87. PMID: PMC4491329.
151. Palanee-Phillips T, Schwartz K, Brown ER, Govender V, Mgodini N, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker L-G, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Naidoo S, Pather A, Phillip J, Husnik M, van der Straten A, Soto-Torres L, **Baeten JM**; MTN-020/ASPIRE Study Team. Characteristics of women enrolled into a randomized clinical trial of dapivirine vaginal ring for HIV-1 prevention. *PLoS One.* 2015;10:e0128857. PMID: 4489588.
152. Ying R, Sharma M, Heffron R, Celum C, **Baeten JM**, Katabira E, Bulya N, Barnabas RV. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. *J Int AIDS Soc.* 2015;18:20013. PMID: 4509901.
153. Celum CL, Delany-Moretlwe S, McConnell M, van Rooyen H, Bekker LG, Kurth A, Bukusi E, Desmond C, Morton J, **Baeten JM**. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. *J Int AIDS Soc.* 2015;18:20227. PMID: 4509892.
154. Khanna A, Roberts ST, Cassels SL, Ying R, John-Stewart G, Goodreau SM, **Baeten JM**, Murnane PM, Celum C, Barnabas RV. Estimating PMTCT's impact on heterosexual HIV transmission: A mathematical modeling analysis. *PLoS One.* 2015;10:e0134271. PMID: 4532442.
155. Pintye J, Ngure K, Curran K, Vusha S, Mugo N, Celum C, **Baeten JM**, Heffron R; Partners PrEP Study Team. Fertility decision-making among Kenyan HIV-serodiscordant couples who recently conceived: implications for safer conception planning. *AIDS Patient Care STDS.* 2015;29:510-6. PMID: 4553369.
156. Masese L, **Baeten JM**, Richardson BA, Bukusi E, John-Stewart G, Graham SM, Shafi J, Kiarie J, Overbaugh J, McClelland RS. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. *AIDS.* 2015;29:1077-85. PMID: 4576156.
157. Pattacini L, Murnane PM, **Baeten JM**, Fluharty TR, Thomas KK, Bukusi E, Katabira E, Mugo N, Donnell D, Lingappa JR, Celum C, Marzinke M, McElrath MJ, Lund JM. Antiretroviral pre-exposure prophylaxis does not enhance immune responses to HIV in exposed but uninfected persons. *J Infect Dis.* 2015;211:1943-52. PMC Journal - In Process.
158. Thomson KA, **Baeten JM**, Mugo NR, Bekker L-G, Celum CL, Heffron R. Tenofovir-based oral PrEP prevents HIV infection among women. *Curr Opin AIDS.* Published online 28 Sep 2015.
159. Pyra M, Heffron R, Mugo NR, Nanda K, Thomas KK, Celum C, Kourtis AP, Were E, Rees H, Bukusi E, **Baeten JM**; HSV/HIV Transmission Study and Partners PrEP Study Teams. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy: a prospective study. *AIDS.* In press. NIHMS: 711405.
160. Murnane PM, Brown ER, Donnell D, Coley RY, Mugo N, Mujugira A, Celum C, **Baeten JM**; Partners PrEP Study Team. Estimating efficacy in a randomized trial with product non-adherence: application of

multiple methods to a trial of pre-exposure prophylaxis for HIV prevention. Am J. Epidemiol. 2015;182:848-56. PMID: 4634306.

161. Barnabas RV, **Baeten JM**, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, Delany-Moretlwe S, Gray G, Rees H, Mujugira A, Ronald A, Stevens W, Kapiga S, Wald A, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis. Published online 08 Jun 2015. PMC Journal - In Process.
162. Weis JF, **Baeten JM**, McCoy CO, Warth C, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Mugo N, Matsen FA, Overbaugh J, Celum C, Lehman DA; Partners PrEP Study Team. PrEP-selected drug resistance decays rapidly after drug cessation. AIDS. In press.
163. Morrison S, John-Stewart G, Egessa JJ, Mubezi S, Kusemererwa S, Bii DK, Bulya N, Mugume F, Campbell JD, Wangisi J, Bukusi EA, Celum C, **Baeten JM**; Partners PrEP Study Team. Rapid antiretroviral therapy initiation for women in an HIV-1 prevention clinical trial experiencing primary HIV-1 infection during pregnancy or breastfeeding. PLoS ONE. 2015; 10:e0140773
164. Ngure K, Heffron R, Vusha S, Curran K, Ngutu M, Mugo N, Celum C, **Baeten JM**. I knew I would be safer. Experiences of Kenyan HIV serodiscordant couples soon after pre-exposure prophylaxis (PrEP) initiation. AIDS Patient Care STDS. In press. PMC Journal - In Process
165. Yacoub R, Nadkarni GN, Welkum D, Konstantinidis I, Boueilh R, Grant RM, Mugwanya K, **Baeten JM**, Wyatt C. Elevations in serum creatinine with tenofovir-based HIV pre-exposure prophylaxis: a meta-analysis of randomized placebo-controlled trials. J Acquir Immune Defic Syndr. In press.
166. Ngure K, Heffron R, Curran K, Vusha S, Ngutu M, Mugo N, Celum C, **Baeten JM**. Experiences of Kenyan HIV serodiscordant couples soon after PrEP initiation. AIDS Patient Care STDs. In press.
167. Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, **Baeten J**. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr. In press.
168. Thomson KA, **Baeten JM**, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11:18-26.

b. Book Chapters

1. **Baeten JM**, Wang C, Celum C. Prevention of HIV. In: Anderson JR, ed. A Guide to the Clinical Care of Women with HIV. 2005 edition. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, 2005. Also available at <http://hab.hrsa.gov/publications/womencare05>.
2. **Baeten JM**, Celum C. Herpes simplex virus and HIV-1. In: Peiperl L, Coffey S, Bacon O, Volberding PA, eds. HIV InSite Knowledge Base [textbook on-line], 2006. Available at <http://hivinsite.ucsf.edu/InSite?page=kb-05-03-02>.
3. **Baeten JM**, Celum C. Syphilis. In: Jong EC, McMullen WR, eds. The Travel and Tropical Medicine Handbook. 4th edition. Saunders/Elsevier Inc., 2008.
4. **Baeten JM**, Celum C. Prevention of HIV Infection. In: Anderson JR, ed. A Guide to the Clinical Care of Women with HIV. 2013 edition. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, 2013. Also available at <http://hab.hrsa.gov/deliverhivaidscafe/files/womenwithaids.pdf>.

c. *Published Books*

None.

d. *Non-Peer Reviewed Publications*

1. **Baeten JM**, Richardson BA, Lavreys L, Rakwar JP, Kreiss JK. Reply to Potterat. *J Infect Dis.* 2005;191:2155-6 [letter].
2. **Baeten JM**, Lavreys L, Sagar M, Kreiss JK, Richardson BA, Chohan B, Panteleeff D, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. *J Acquir Immune Defic Syndr.* 2005;38:S18-20 [conference proceedings].
3. McClelland RS, **Baeten JM**. Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals. *J Antimicrob Chemother* 2006;57:163-6 [review].
4. McClelland RS, Ndinya-Achola JO, **Baeten JM**. Response to “Is vaginal washing associated with increased risk of HIV-1 acquisition?” *AIDS.* 2006;20:1348-9 [letter].
5. **Baeten JM**, Celum C. HIV infected but unaware: a prevention opportunity. *Clinical Care Options for HIV.* Available at http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Marks_AIDS_2006_07/Commentary.aspx [commentary].
6. McClelland RS, Ndinya-Achola JO, **Baeten JM**. Re: distinguishing the temporal association between women’s intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. *Am J Epidemiol.* 2007;165:474-5 [letter].
7. **Baeten JM**. Dual HIV infection without disease progression. *AIDS Clin Care.* 2008;20:22 [commentary].
8. **Baeten JM**. New biomedical strategies for HIV-1 prevention in women. *Curr Infect Dis Rep.* 2008;10:490-8 [review].
9. **Baeten JM**, Celum C. HIV prevention at CROI 2009. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
10. **Baeten JM**, Celum C, Coates TJ. Male circumcision and HIV risks and benefits for women. *Lancet.* 2009;374:182-4 [commentary].
11. **Baeten JM**, Celum C. HIV prevention at IAS 2009. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
12. **Baeten JM**, Celum C, Coates TJ. Authors’ reply. *Lancet* 2009;374:1498 [letter].
13. **Baeten JM**, Celum C. HIV prevention at CROI 2010. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
14. **Baeten JM**, Celum C. HIV prevention at AIDS 2010. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
15. **Baeten, JM**. Adherence in HIV type 1 prevention trials. *J Infect Dis.* 2010;201:1279-81 [commentary].
16. Kurth AE, Celum C, **Baeten JM**, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. *Curr HIV/AIDS Rep.* 2011;8:62-72 [review]. PMID: 3036787.
17. **Baeten JM**, Celum C. HIV prevention at CROI 2011. NATAP / National AIDS Treatment Advocacy

Project. Available at <http://www.natap.org/> [review].

18. **Baeten JM**, Celum C. HIV prevention at IAS 2011. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
19. Celum C, **Baeten JM**. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. *Curr Opin Infect Dis*. 2012;25:51-7 [review]. PMID: 3266126.
20. **Baeten JM**, Celum C. HIV prevention at CROI 2012. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
21. Heffron R, Rees H, Mugo N, **Baeten JM**. Use of hormonal contraceptives and risk of HIV-1 transmission – Authors’ reply. *Lancet Infect Dis*. 2012;12:510-1 [letter].
22. **Baeten JM**. Antiretroviral treatment for HIV prevention: current considerations. Medscape Education. <http://www.medscape.org/viewprogram/32564> [review].
23. **Baeten JM**, Celum C. HIV prevention at AIDS 2012. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
24. **Baeten JM**, Celum C. Oral antiretroviral chemoprophylaxis: current status. *Curr Opin HIV AIDS*. 2012;7:514-9 [review]. PMID: 3501411.
25. Celum C, **Baeten JM**. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. *Antivir Ther*. 2012;17:1483-93 [review]. PMID: 3531985.
26. **Baeten JM**, Celum C. Authors’ reply. *N Engl J Med*. 2013;368:83-4 [letter].
27. **Baeten J**, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. *Annu Rev Med*. 2013;64:219–32 [review]. PMID: 3730272.
28. **Baeten JM**, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don’t we know? *Curr HIV/AIDS Rep*. 2013;10:142-51 [review]. PMID: 3644362.
29. Celum C, **Baeten JM**. Serodiscordancy and HIV prevention in sub-Saharan Africa. *Lancet* 2013;38:1519-21 [commentary].
30. Celum C, Hallett T, **Baeten JM**. HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness and public health impact. *J Infect Dis*. 2013;208:189-91 [commentary]. PMID: 3685227.
31. **Baeten JM**, Celum C. HIV prevention at CROI 2013. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
32. **Baeten JM**, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? *J Acquir Immune Defic Syndr*. 2013;63:S122-9 [review]. PMID: 3710117.
33. Celum C, **Baeten JM**, Hughes JP, Barnabas R, Liu A, van Rooyen H, Buchbinder S. Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. *J Acquir Immune Defic Syndr*. 2013;63:S213-20 [review]. PMID: 3708491.
34. **Baeten JM**, Mujugira A, Celum C. HIV prevention at IAS 2013. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
35. Campbell M, Kahle EK, **Baeten JM**. Reply to Neogi et al. *J Infect Dis*. 2013;208:867-8 [letter].

36. Wilcher R, Cates W, **Baeten JM**. Family planning and HIV: two steps forward.... AIDS. 2013;27:S1-4 [commentary].
37. Cates W; Evidence for Contraceptive Options and HIV Outcomes (ECHO) Consortium. Research on hormonal contraception and HIV. Lancet. 2014;383:303-4 [letter, member of writing team].
38. **Baeten JM**, Heffron R. Pre-exposure prophylaxis to intensify the fight against HIV. Lancet Infect Dis. 2014;14:443-5 [commentary].
39. **Baeten JM**, Celum C. HIV prevention at CROI 2014. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
40. **Baeten JM**, Ngure K, Celum C. HIV prevention at AIDS 2014. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
41. Rees H; ECHO Consortium. DMPA and HIV: why we need a trial. Contraception 2014;90:354-6 [commentary, member of writing team].
42. **Baeten JM**, Celum C. HIV prevention at CROI 2015. NATAP / National AIDS Treatment Advocacy Project. Available at <http://www.natap.org/> [review].
43. **Baeten JM**, Heffron R. Contraception and sexually transmitted infections: weighing risks and benefits, hypotheses and evidence. Lancet Glob Health. 2015;3:e430-1 [commentary].
44. Wyatt C, **Baeten JM**. Tenofovir alafenamide for HIV infection: is less more? Lancet. In press [commentary].
45. Dhanireddy S, **Baeten JM**. Tenofovir alafenamide for HIV treatment: time to switch? Submitted [commentary]. Lancet Infect Dis. In press.
46. **Baeten JM**, McCormack S. Welcome to the PrEP revolution. Curren Opinion in HIV/AIDS. In press.

e. *Submitted Manuscripts*

1. Smith JA, Heffron R, Butler A, Celum C, **Baeten JM**, Hallett TB. Could misreporting of condom use explain the observed association between injectable contraceptives and HIV acquisition risk? Submitted.
2. Ying R, Sharma M, Celum C, **Baeten JM**, van Rooyen H, Hughes JP, Garnett G, Barnabas RV. Home HIV testing and counseling cost-effectively reduces HIV incidence in a generalized epidemic setting: a mathematical modeling analysis. Submitted.
3. Andersen-Nissen E, Chang JT, Thomas KK, Adams D, Celum C, Sanchez J, Coombs RW, McElrath MJ, **Baeten JM**. Herpes simplex virus (HSV) suppressive therapy in HSV-2/HIV-1 co-infected women is associated with reduced systemic CXCL10 but not genital cytokines. Submitted.
4. Irungu E, Heffron R, Mugo N, Ngure K, Katabira E, Bulya N, Bukusi E, Odoyo J, Asimwe S, Tindimwebwa E, Celum C, **Baeten JM**; Partners Demonstration Project Team. Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. Submitted.
5. Pattacini L, **Baeten JM**, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Bukusi E, Ronald A, Mugo N, Lingappa JR, Celum C, McElrath MJ, Lund JM. Increased levels of regulatory T-cells correlate with protection from HIV infection. Submitted.
6. Musinguzi N, Muganzi CD, Boum Y, Ronald A, Celum C, **Baeten J**, Bangsberg DR, Haberer JE; Partners PrEP Ancillary Adherence Study Team. Comparison of subjective and objective adherence measures for pre-exposure prophylaxis against HIV infection among serodiscordant couples in East Africa: an analysis

from the Partners PrEP Ancillary Adherence Study. Submitted.

7. **Baeten JM**, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, Asimwe S, Haberer JE, Morton J, Ngure K, Bulya N, Odoyo J, Tindimwemba E, Hendrix C, Marzinke M, Ware N, Wyatt M, Morrison S, Haugen H, Mujugira A, Donnell D, Celum C; Partners Demonstration Project Team. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis results in near elimination of HIV-1 transmission among African HIV-1 serodiscordant couples: a prospective implementation study. Submitted.
8. Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, **Baeten JM**, Babigumira J, Garrison LP, Stergachis A. Sentinel site active surveillance of first-line antiretroviral medicines in Namibia. Submitted.
9. Heffron R, Parkih UM, Penrose KJ, Mugo N, Donnell D, Celum C, Mellors JW, **Baeten JM**. Objective measurement of inaccurate condom use reporting shows similar frequency among women using depot medroxyprogesterone acetate and no hormonal contraception. Submitted.
10. Dhanireddy S, **Baeten JM**. Tenofovir alafenamide for HIV treatment: time to switch? Submitted [comment].
11. Heffron R, Cohen CR, Ngure K, Bukusi E, Were E, Kiarie J, Mugo N, Celum C, **Baeten JM**; Partners PrEP Study, Partners in Prevention HSV/HIV Transmission Study, and the Partners Demonstration Project Teams. A scoring tool to identify East African HIV-1 serodiscordant partnerships with a high likelihood of pregnancy. PLoS One. Submitted
12. Barnabas RV, van Rooyen H, Tumwesigye E, Brantley J, **Baeten JM**, van Heerden A, Turyamureeba B, Joseph P, Krows M, Thomas KK, Schaafsma T, Hughes JP, Celum C. Uptake of antiretroviral therapy and male circumcision following community-based HIV testing linkage strategies versus referral: A randomized, multisite, open-label, individual trial in South Africa and Uganda. Submitted.
13. Roberts ST, Khanna AS, Barnabas RV, Goodreau SM, **Baeten JM**, Celum C, Cassels S. Estimating the impact of immediate ART for serodiscordant couples through home HIV testing: Insights from mathematical models. Submitted.
14. Carroll JJ, Ngure K, Heffron R, Curran K, Mugo NR, **Baeten JM**. Gendered differences in the perceived risks and benefits of oral PrEP among HIV serodiscordant couples in Kenya. AIDS Care. Submitted.
15. Carroll JJ, Heffron R, Mugo N, Ndase P, Asimwe S, Celum C, **Baeten JM**. Perceived risk among HIV serodiscordant couples in East Africa taking oral PrEP. Submitted.
16. Njuguna N, Ngure K, Mugo N, Sambu C, Siano C, Gakuo S, Irungu E, **Baeten J**, Heffron R. The effect of HIV prevention and reproductive health text messages on HIV testing among young women in rural Kenya: a pilot study. Submitted.
17. Ngure K, Vusha S, Mugo N, Emmanuel-Fabula M, Ngutu M, Celum C, Baeten J, Heffron R. "I never thought that it would happen ..." Experiences of HIV seroconverters among HIV discordant partnerships in a prospective HIV prevention study in Kenya. Submitted
18. **Baeten JM**, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodini NM, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker L-G, Jeenaarain N, Gaffoor Z, Martinson F, Makani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Schechter R, Berthiaume J, Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, Singh D, Szydio DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S; MTN-020/ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. Submitted.
19. Heffron R, Parikh UM, Penrose KJ, Mugo N, Donnell D, Celum C, Mellors JW, **Baeten JM**; Partners PrEP Study Team. Objective measurement of inaccurate condom use reporting among women using

depot medroxyprogesterone acetate for contraception. Submitted.

f. Abstracts

1. **Baeten JM**, Bothwell M, Sudra AH, von Bartheld CS. Quantification of anterogradely-transported neurotrophin-3 and measurement of its release from retinal ganglion cell axon terminals in the developing chick optic tectum. Western Student Medical Research Forum, Carmel, California, USA, March 3-7, 1997. Abstract in J Invest Med. 1997;45:109A.
2. **Baeten JM**, Richardson BA, Martin HL, Nyange PM, Lavreys K, Ngugi EN, Mandalilya K, Ndinya-Ahcola JO, Bwayo JJ, Kreiss JK. Trends in HIV-1 incidence in a cohort of prostitutes in Mombasa, Kenya: implications for HIV-1 vaccine efficacy. 11th International Conference on STD/AIDS in Africa, Lusaka, Zambia, September 12-16, 1999. Abstract 13DT5-2.
3. **Baeten J**, Mostad S, Hughes M, Overbaugh J, Bankson D, Mandalilya K, Ndinya-Achola J, Bwayo J, Kreiss J. Selenium deficiency is associated with shedding of HIV-1 infected cells in the female genital tract. XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000. Abstract MoOrA226.
4. **Baeten J**, Richardson B, Martin H, Nyange P, Lavreys L, Ngugi E, Mandalilya K, Bwayo J, Kreiss J. Rapid decline in risk of HIV-1 acquisition after enrollment in a vaccine preparedness cohort of Kenyan prostitutes: implications for the design of HIV-1 vaccine efficacy trials. XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000. Abstract MoOrC128.
5. Lavreys L, Overbaugh J, **Baeten J**, Panteleeff D, Martin H Jr, Ogwen G, Mandalilya K, Ndinya-Achola J, Bwayo J, Kreiss J. Viral load during primary HIV-1 infection in a cohort of female commercial sex workers in Mombasa, Kenya. XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000. Abstract MoPeB2247.
6. Lavreys L, **Baeten JM**, Overbaugh J, Panteleeff DD, Chohan BH, Richardson BA, Mandalilya K, Ndinya-Achola JO, Kreiss JK. Acute HIV-1 infection illness is associated with higher viral load among women in Mombasa, Kenya. XII International Conference on AIDS and STDs in Africa, Ouagadougou, Burkina Faso, December 9-14, 2001. Abstract 10PT3-215.
7. Sagar M, Lavreys L, **Baeten J**, Richardson B, Mandalilya K, Kreiss J, Overbaugh J. Correlates of viral diversity in primary HIV-1 infection in women. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, February 24-28, 2002. Abstract 100.
8. Overbaugh J, Sagar M, Benki S, Lavreys L, Richardson B, **Baeten J**, Long EM, Panteleeff D, Mandalilya K, Bwayo J, Ndinya-Achola J, Kreiss J. Viral and host factors in HIV-1 transmission and pathogenesis. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, February 24-28, 2002. Abstract S23.
9. Lavreys L, **Baeten JM**, Kreiss JK, Richardson BA, Panteleeff D, Chohan B, Mandalilya K, Bwayo J, Overbaugh J. Natural history and covariates of HIV-1 viremia among women in Mombasa, Kenya. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract TuPeC4708.
10. McClelland RS, **Baeten JM**, Overbaugh J, Richardson BA, Mandalilya K, Emery S, Lavreys L, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Effect of multivitamin supplementation on genital tract shedding of human immunodeficiency virus type 1: results of a randomized trial. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract WePeB5987.
11. **Baeten JM**, McClelland RS, Overbaugh J, Richardson BA, Emery S, Lavreys L, Mandalilya K, Bankson DD, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Vitamin A supplementation and HIV-1 shedding in women: results of a randomized clinical trial. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract WePeB5989.

12. **Baeten JM**, Chohan BH, Lavreys L, Rakwar JP, Ashley R, Richardson BA, Mandaliya K, Bwayo JJ, Kreiss JK. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract ThPeC7539.
13. **Baeten JM**, Lavreys L, Sagar M, Kreiss JK, Richardson BA, Chohan B, Panteleeff D, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Effect of contraceptive method on natural history of HIV. National Institutes of Health: Fertility Regulation and Systemic Hormones in HIV-Infected and At-Risk Women, McLean, Virginia, USA, January 13-14, 2003.
14. **Baeten JM**, Kreiss JK, Lavreys L, McClelland RS, Sagar M, Martin HM, Richardson BA, Chohan B, Panteleeff D, Emery S, Mandaliya K, Ndinya-Achola JO, Bwayo J, Overbaugh J. The influence of vitamin A and hormonal contraception on HIV transmission and disease progression in women. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 10-14, 2003. Abstract 116.
15. Lavreys L, **Baeten JM**, Martin HL Jr., Kreiss JK, Mandaliya K, Ndinya-Achola J, Overbaugh J. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003. Abstract 83.
16. McClelland RS, **Baeten JM**, Ashley Morrow RL, Corey L, Lavreys L, Rakwar JP, Mandaliya K, Bwayo JJ, Holmes KK, Kreiss JK. Seroconversion for human herpesvirus type 8 among Kenyan truck drivers. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003. Abstract 928.
17. McClelland RS, **Baeten JM**, Overbaugh J, Mandaliya K, Ndinya-Achola JO, Kreiss JK. Infrequent detection of HIV-1 in the genital tract of women with low plasma HIV-1 RNA: implications for sexual transmission. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003. Abstract 1158.
18. Lavreys L, **Baeten JM**, Chohan V, McClelland RS, Overbaugh J, Mandaliya K, Ndinya-Achola JO. Hormonal contraception and risk of cervical infections among HIV-1 seropositive women in Mombasa, Kenya. 13th International Conference on STD/AIDS in Africa, Nairobi, Kenya, September 21-26, 2003. Abstract 777726.
19. Hassan WM, **Baeten JM**, Lavreys L, Chohan V, Mandaliya K, Ndinya-Achola JO, McClelland RS. Vaginal infections, intravaginal practices, and the risk of HIV-1 acquisition: a 10-year prospective study. 13th International Conference on STD/AIDS in Africa, Nairobi, Kenya, September 21-26, 2003. Abstract 705400.
20. Katingima C, **Baeten JM**, Lavreys L, Mandaliya K, Ndinya-Achola JO, McClelland RS. Vaginal infections and HIV-1 serostatus among female sex workers in Mombasa, Kenya. 13th International Conference on STD/AIDS in Africa, Nairobi, Kenya, September 21-26, 2003. Abstract 249143.
21. Lavreys L, **Baeten JM**, Kreiss JK, Sagar M, Martin HM, Richardson BA, Chohan B, Panteleeff D, Mandaliya K, Ndinya-Achola JO, Overbaugh J. The influence of hormonal contraception on HIV transmission and disease progression in women. 10th Reproductive Health Priorities Conference, Johannesburg, South Africa, October 14-17, 2003. Abstract 43.
22. Chohan B, DeVange S, Sagar M, Panteleeff D, Lavreys L, **Baeten J**, Richardson B, Kreiss J, Overbaugh J. Pathogenesis and transmission of HIV-1 subtypes and intersubtype recombinants. 21st Annual Symposium on Nonhuman Primate Models for AIDS, Seattle, Washington, USA, October 22-25, 2003. Abstract 36.
23. Drain PK, **Baeten JM**, Overbaugh J, Wener M, Lavreys L, Mandaliya K, Ndinya-Achola JO, Holmes KK, McClelland RS. Effects of albumin and the acute phase response on serum selenium in HIV-1 infected women. Western Student Medical Research Forum, Carmel, California, USA, January 28-31, 2004.

24. Drain PK, **Baeten JM**, Overbaugh J, Wener M, Lavreys L, Mandaliya K, Ndinya-Achola JO, McClelland RS. Effects of low serum albumin and the acute phase response on serum selenium in HIV-1 infected women. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. Abstract MoPeC3393.
25. Lavreys L, **Baeten JM**, Chohan V, McClelland RS, Richardson BA, Mandaliya K, Ndinya-Achola J, Overbaugh J. Set point viral load, early CD4, and acute HIV-1 illness are associated with mortality among HIV-1 infected Kenyan women. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. Abstract MoPeC3394.
26. McClelland RS, Lavreys L, Katingima C, Overbaugh J, Chohan V, Mandaliya K, Ndinya-Achola J, **Baeten JM**. Contribution of HIV-1 infection to STD acquisition: a ten-year prospective study. 42nd Annual Meeting of the Infectious Disease Society of America (IDSA), Boston, Massachusetts, USA, September 30 - October 3, 2004. Abstract 797.
27. **Baeten JM**, Richardson BA, Lavreys L, Rakwar JP, Mandaliya KM, Bwayo JJ, Kreiss JK. Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men. 42nd Annual Meeting of the Infectious Disease Society of America (IDSA), Boston, Massachusetts, USA, September 30 - October 3, 2004. Abstract 846.
28. **Baeten J**, Lavreys L, Richardson B, McClelland RS, Panteleeff D, Chohan V, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Correlates of cervical HIV-1 shedding during early HIV-1 infection. Massachusetts General Hospital Clinical Research Day 2005, Boston, Massachusetts, USA, June 28, 2005. Abstract 11.
29. McClelland RS, Lavreys L, Hassan WM, Mandaliya KN, Ndinya-Achola JO, **Baeten JM**. Intravaginal washing and increased risk of HIV-1 acquisition among Kenyan women: a 10-year prospective cohort study. 16th Biennial Meeting of the International Society for Sexually Transmitted Disease Research, Amsterdam, Netherlands, July 10-13, 2005. Abstract MO-002.
30. McClelland RS, **Baeten JM**, Richardson BA, Lavreys L, Emery S, Mandaliya KN, Ndinya-Achola JO, Overbaugh J. Antiretroviral treatment guidelines, infectivity, and sexual risk in Kenyan women: implications for the potential impact of antiretrovirals on HIV transmission. 16th Biennial Meeting of the ISSTD International Society for Sexually Transmitted Disease Research, Amsterdam, Netherlands, July 10-13, 2005. Abstract MP-026.
31. **Baeten JM**. Epidemiology of HIV-1 among adolescents and young adults. AIDS Vaccine 2005, Montreal, Canada, September 6-9, 2005. Abstract 146.
32. McClelland RS, Lavreys L, Hassan W, Mandaliya K, Kiarie J, Ndinya-Achola J, Jaoko W, **Baeten J**. Infection with *Trichomonas vaginalis* increases the risk for HIV-1 acquisition: a prospective study. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, Colorado, USA, February 5-8, 2006. Abstract 131.
33. Graham S, **Baeten J**, Richardson B, Bankson D, Lavreys L, Ndinya-Achola J, Mandaliya K, Overbaugh J, McClelland R. Higher pre-seroconversion vitamin E levels are associated with more rapid HIV-1 disease progression. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, Colorado, USA, February 5-8, 2006. Abstract 290.
34. McClelland RS, Lavreys L, Richardson B, Mandaliya K, Ndinya-Achola J, **Baeten J**. A prospective study of changes in sexual risk behavior among Kenyan female sex workers before versus after HIV-1 seroconversion. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, Colorado, USA, February 5-8, 2006. Abstract 915.

35. **Baeten JM**, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression compared with subtype A in spite of similar plasma HIV-1 loads. 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, California, USA, February 25-28, 2007. Abstract 68.
36. Lingappa J, Mujugira A, Mugo N, **Baeten J**, Ndase P, Ronald A, Katabira E, Barnes L, Celum C. Possible interventions to prevent HIV transmission and acquisition among African HIV-discordant couples: HSV-2 suppression and pre-exposure antiretroviral prophylaxis. 1st International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Poor Settings, Kampala, Uganda, May 30- June 2, 2007. Abstract 13.
37. Manhart LE, Mostad SB, **Baeten JM**, Overbaugh J, Astete SG, Mandaliya K, Totten PA. High *Mycoplasma genitalium* organism burden is associated with shedding of HIV-1 infected cells from the cervix. 17th Meeting of the International Society for Sexually Transmitted Disease Research (ISSTD), Seattle, Washington, USA, July 29 - August 1, 2007. Abstract O-003.
38. **Baeten JM**, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. 17th Meeting of the International Society for Sexually Transmitted Disease Research (ISSTD), Seattle, Washington, USA, July 29 - August 1, 2007. Abstract O-049.
39. **Baeten JM**, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Margaret A, Wald A, Corey L, Celum C. Herpes simplex virus suppressive treatment decreases plasma HIV-1 viral load in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial. 17th Meeting of the International Society for Sexually Transmitted Disease Research (ISSTD), Seattle, Washington, USA, July 29 - August 1, 2007. Abstract O-096.
40. Piantadosi A, Chohan B, Panteleeff D, Jalalian-Lechak Z, **Baeten J**, Overbaugh J. Evolution in HIV-1 *gag* and *env* is differentially associated with viral load and the immune response at different times in infection. 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 3-6, 2008. Abstract 311.
41. **Baeten J**, Strick L, Lucchetti A, Whittington W, Sanchez J, Coombs R, Margaret A, Wald A, Corey L, Celum C. Herpes simplex virus suppressive treatment decreases plasma and genital HIV-1 viral loads in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial. 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 3-6, 2008. Abstract 676.
42. Curlin M, Celum C, Sanchez J, Selke S, **Baeten J**, Huang M-L, Corey L. The natural history of adenovirus in mucosal tissues of the lower gastrointestinal tract in men who have sex with men. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, February 8-11, 2009. Abstract 403.
43. Manhart L, McClelland RS, **Baeten J**, Masese L, Ndinya-Achola JO, Jaoko W, Totten PA. Incident *Mycoplasma genitalium* infection among Kenyan women is associated with bacterial vaginosis. 18th International Society for STD Research (ISSTD), London, United Kingdom, June 28 - July 1, 2009. Abstract P3.37.
44. Mugwanya K, **Baeten J**, Whalen CC, Celum C, Nakku-Joloba E, Katabira E. Attitudes towards circumcision of male children for prevention of HIV-1: a study among heterosexual HIV-1 serodiscordant couples in Kampala, Uganda. 18th International Society for STD Research (ISSTD), London, United Kingdom, June 28 - July 1, 2009. Abstract P4.60.
45. **Baeten JM**, Donnell D, Mujugira A, Ndase P, Mugo N, Kidoguchi L, Barnes L, Lingappa J, Celum C; Partners PrEP Study Team. Characteristics of HIV-1 serodiscordant couples enrolled into a clinical trial of antiretroviral chemoprophylaxis: the Partners PrEP Study. 5th International AIDS Society (IAS)

Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract WEPEC079.

46. **Baeten JM**, Kahle E, Lingappa JR, Coombs RW, Donnell D, Wald A, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA concentrations and heterosexual HIV-1 transmission risk. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract LBPEA07.
47. **Baeten JM**, Donnell D, Inambao M, John-Stewart G, Kapiga S, Manongi R, Ronald A, Vwalika B, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Male circumcision and male-to-female HIV-1 transmission risk: a multinational prospective study. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract LBPEC06.
48. Mugwanya K, **Baeten J**, Whalen C, Celum C, Nakku-Joloba E, Katabira E. Knowledge and attitudes regarding male circumcision for HIV-1 prevention among heterosexual HIV-1 serodiscordant couples in Kampala, Uganda. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract MOPDC102.
49. Jacob S, **Baeten J**, Hughes J, Wang J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Buchbinder S, Koblin B, Celum C. HPTN 039 Protocol Team. Medication adherence in biomedical HIV-1 prevention trials: a post-trial assessment. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract MOPEC027.
50. Chersich MF, Martin Hilber A, Schmidlin K, Egger M, Francis S, **Baeten J**, Brown J, Delany-Moretlwe S, Hayes R, Kaul R, Luchters S, McGrath N, Myer L, Rees H, Temmerman M, Van der Straten A, Van de Wijgert J, Watson-Jones D, Zwahlen M, Low N. Association between intravaginal practices and HIV acquisition in women: individual patient data meta-analysis of cohort studies in sub-Saharan Africa. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract TUAC204.
51. Celum C, Wald A, Lingappa J, Magaret A, Wang R, Mugo N, Mujugira A, **Baeten J**, Mullins J, Hughes J, Bukusi E, Cohen C, Katabira E, Ronald A, Kiarie J, Farquhar C, John Stewart G, Makhema J, Essex M, Were E, Fife K, deBruyn G, Gray G, McIntyre J, Monongi R, Kapiga S, Coetzee D, Allen S, Inambao I, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell M, Thomas K, Coombs R, Morrow R, Whittington W, McElrath MJ, Barnes L, Ridzon R, Corey L. Partners in Prevention HSV-HIV Transmission Team. Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1/HSV-2 co-infected persons within HIV-1 serodiscordant couples: a randomized, double-blind, placebo-controlled trial. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract WELBC101.
52. Lingappa J, **Baeten JM**, Wald A, Hughes J, Thomas KK, Mujugira A, Mugo N, Bukusi E, Cohen C, Katabira E, Ronald A, Kiarie J, Farquhar C, John Stewart G, Makhema J, Essex M, Were E, Fife K, deBruyn G, Gray G, McIntyre J, Monongi R, Kapiga S, Coetzee D, Allen S, Inambao I, Kayitenkore K, Karita E, Kanweka W, Delany-Moretlwe S, Rees H, Vwalika B, Magaret A, Wang R, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C. Partners in Prevention HSV-HIV Transmission Team. Daily acyclovir delays HIV-1 disease progression among HIV-1/HSV-2 dually-infected persons: a randomized trial. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Abstract WELBC102.
53. Curlin M, Celum C, Sanchez J, Selke S, **Baeten J**, Huang M-L, Zuckerman R, Lu X, Erdman D, Corey L. Intermittent rectal shedding of diverse Adenovirus types among HIV-positive MSM. AIDS Vaccine 2009, Paris, France, October 19-22, 2009. Abstract 164766.
54. Lingappa J, Hughes J, Donnell D, **Baeten J**, Gray G, Mullins J, Campbell M, Essex M, Farquhar C, Rees H, Stevens W, Wald A, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

HIV-1 plasma RNA and risk of HIV-1 transmission. AIDS Vaccine 2009, Paris, France, October 19-22, 2009. Abstract OA01-06 LB.

55. **Baeten J**, Ndase P, Mugo N, Donnell D, Mujugira A, Kidoguchi L, Barnes L, Celum C; Partners PrEP Study Team. Demographic, behavioral, and clinical characteristics of HIV-1 serodiscordant couples enrolled into an efficacy trial of pre-exposure prophylaxis. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, California, USA, February 16-19, 2010. Abstract 959.
56. Donnell D, Kiarie J, Thomas K, **Baeten J**, Lingappa J, Cohen C, Celum C. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, California, USA, February 16-19, 2010. Abstract 136.
57. **Baeten J**, Lingappa J, Corey L, Wald A, Beck I, Frenkel L, Pepper G, Mugo N, Sanchez J, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not induce specific HIV-1 resistance in HSV-2/HIV-1 dually-infected persons. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, California, USA, February 16-19, 2010. Abstract 91.
58. Campbell M, Mullins J, Hughes J, Celum C, Kahle E, Panteleeff D, **Baeten J**, Lingappa J; Partners in Prevention HSV/HIV Transmission Study Team. Epidemiologic characteristics associated with HIV-1 transmission linkage among serodiscordant couples in an HIV-1 prevention clinical trial. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, California, USA, February 16-19, 2010. Abstract 970.
59. Mugo N, Heffron R, Donnell D, Were E, Kiarie J, Kayitenkore K, Cohen C, Celum C, Wald A, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Pregnancy is associated with an increased risk for HIV transmission among African HIV-1 serodiscordant couples. Microbicides 2010, Pittsburgh, Pennsylvania, USA, May 22-25, 2010. Abstract 8.
60. Ngure K, Mwaniki L, Mwaniki P, Irungu E, **Baeten J**, Mugo N. High uptake of non-barrier contraception by women before randomization into an HIV prevention trial in rural Kenya. Microbicides 2010, Pittsburgh, Pennsylvania, USA, May 22-25, 2010. Abstract 324.
61. Mujugira A, **Baeten J**, Ndase P, Mugo N, Donnell D, Kidoguchi L, Barnes L, Celum C; Partners PrEP Study Team. HIV-1 risk characteristics of HIV-1 serodiscordant couples enrolled into an efficacy trial of pre-exposure prophylaxis. Microbicides 2010, Pittsburgh, Pennsylvania, USA, May 22-25, 2010. Abstract 426.
62. **Baeten J**, Mugo N, Ndase P, Mujugira A, Donnell D, Kidoguchi L, Barnes L, Celum C; Partners PrEP Study Team. The Partners PrEP Study: enrollment of HIV-1 serodiscordant couples into a phase III, randomized trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. XVIII International AIDS Conference, Vienna, Austria, July 18-23, 2010. Abstract MOPE0377.
63. **Heffron R**, Mugo N, Celum C, Baeten J. Contraceptive method and pregnancy risk among African women in HIV-1 serodiscordant partnerships. CFAR Joint Symposium on HIV Research in Women, Chicago, Illinois, USA, 2010.
64. Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath JM, **Baeten JM**, Celum C, de Bruyn G, Nakku-Joloba E, Farquhar C., Essex M, Donnell D, Haynes BF, Goldstein D; Partners in Prevention HSV/HIV Transmission Study Team. Genome-wide association study among African heterosexual serodiscordant couples for host genetic factors associated with HIV-1 acquisition/resistance and plasma HIV-1 set point. AIDS Vaccine 2010, Atlanta, Georgia, USA, September 28 - October 1, 2010. Abstract P07.07 LB.
65. Lingappa JR, **Baeten JM**, Thomas K, Donnell D, De Bruyn G, Nakku-Joloba E, Farquhar C, McElrath MJ,

Essex M, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Exposure risk score to identify HIV-1 exposed seronegative individuals. AIDS Vaccine 2010, Atlanta, Georgia, USA, September 28 - October 1, 2010. Abstract P21.13 LB.

66. Hallett T, **Baeten J**, Heffron R, de Bruyn G, Delany-Moretlwe S, Gray G, Johnson L, McIntyre J, Rees H, Celum C. ART or PrEP for HIV prevention in HIV serodiscordant partnerships: a mathematical modeling comparison. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 99LB.
67. Lingappa J, Thomas K, Hughes J, **Baeten J**, Fife K, de Bruyn G, Farquhar C, Kapiga S, Makhema J, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Infected partner's plasma HIV-1 RNA level and the HIV-1 set point of their heterosexual seroconverting partners. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 134.
68. Hughes J, **Baeten J**, Lingappa J, Magaret A, Wald A, de Bruyn G, Kiarie J, Inambao M, Farquhar C, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-act infectivity of HIV-1 in the Partners in Prevention Study. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 135.
69. **Baeten J**, Kahle E, Lingappa J, Coombs R, Delany-Moretlwe S, Nakku-Joloba E, Mugo N, Wald A, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA levels predict risk of heterosexual HIV-1 transmission. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 154.
70. Haberer J, **Baeten J**, Celum C, Tumwesigye E, Katabira E, Krows M, Kidoguchi L, Donnell D, Mujugira A, Bangsberg D. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP Study. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 488.
71. Mackelprang R, **Baeten J**, Donnell D, Celum C, Farquhar C, de Bruyn G, Essex M, Nakku-Joloba E, McElrath J, Lingappa J; Partners in Prevention HSV/HIV Transmission Study Team. Longitudinal HIV-1 exposure profiles among HIV-discordant couples. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 1029.
72. Ndase P, Celum C, Thomas K, Donnell D, Bukusi E, Fife K, Delany-Moretlwe S, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Sexual behavior and HIV-1 risk for HIV-1-uninfected partners in African HIV-1 serodiscordant partnerships. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 27 - March 2, 2011. Abstract 1040.
73. Ware NC, Wyatt MA, Haberer J, **Baeten J**, Celum CL, Bangsberg DR. "What's Love Got to Do With It?" A relationship framework for research on adherence to antiretroviral therapy (ART) as pre-exposure prophylaxis. 6th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, May 22-24, 2011. Abstract 70018.
74. Psaros C, Bangsberg DB, Haberer J, Mujugira A, Kintu A, Mugwanya K, Enyakoit M, Tumwesigye E, Katabira E, Nakku-Joloba E, Kakia A, Wangisi J, **Baeten J**, Celum C, Safren SA. An adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in sero-discordant couples in Uganda. 6th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, May 22-24, 2011. Abstract 70065.
75. Ngure K, **Baeten J**, Lingappa J, Heffron R, Musingila P, Irungu E, Mwaniki P, Mwaniki L, Wamae R, Mburu S, Mugo N. Contraceptive discontinuation by rural Kenyan women in HIV discordant partnerships after exiting an HIV prevention trial. International Society of STD Research, Quebec, Canada, July 10-13, 2011. Abstract P1-S6.02.

76. **Baeten JM**, Celum C; Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract MOAX0106.
77. Cohen CR, Lingappa JR, **Baeten JM**, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA; Partners in Prevention HSV/HIV Transmission Study Team. Association of bacterial vaginosis with female-to-male HIV-1 transmission among HIV-1 discordant couples in sub-Saharan Africa. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract MOAC0202.
78. Tumwesigye E, **Baeten J**, Tumwebaze H, Kurth A, Revall J, Chang L, Murnane P, Celum C. Potential of household-based HIV counseling and testing as a platform for targeted referral to HIV prevention and care in Uganda. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract MOLBPE045.
79. Ngayo MO, Bukusi EA, Spiegel C, Mwangi JN, Maina MK, Lingappa JR, **Baeten JM**, Hong T, Donnell D, Kiarie J, Wald A, Cohen CR; Partners in Prevention HSV/HIV Transmission Study Team. Association of abnormal vaginal flora with male-to-female HIV-1 transmission among HIV-1 discordant couples in sub-Saharan Africa. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract TUPE188.
80. Donnell D, **Baeten J**, Hong T, Mujugira A, Nakku-Joloba E, Bangsberg D, Lingappa J, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Using biological effects to assess whether pill counts are an accurate measure of adherence in a biomedical HIV-1 prevention study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract TUPE354.
81. Heffron R, Donnell D, Rees H, Celum C, Were E, Mugo N, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract WEAX0206.
82. Mugwanya K, **Baeten J**, Mugo N, Irungu E, Ngure K, Celum C. High-dose valacyclovir suppressive therapy results in greater reduction in plasma HIV-1 levels compared to standard dose acyclovir suppression among HIV-1/HSV-2 co-infected persons: a randomized, open-label, crossover trial. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract WEPDB0106.
83. Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, Rees H, Kiarie J, Thomas K, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Hormonal contraceptive use and risk of HIV-1 disease progression. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 21.
84. **Baeten J**, Donnell D, Ndase P, Mugo N, Mujugira A, Celum C; Partners PrEP Study Team. ARV PrEP for HIV-1 prevention among heterosexual men and women. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 29.
85. Donnell D, **Baeten J**, Hendrix C, Bumpus N, Bangsberg D, Haberer J, Mujugira A, Celum C; Partners PrEP Study Team. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 30.
86. Blish C, McClelland S, Richardson B, Jaoko W, Mandaliya K, **Baeten J**, Overbaugh J. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 55.

87. Campbell M, Kahle E, Celum C, Lingappa J, Kapiga S, Mujugira A, Mugo N, Fife K, Mullins J, **Baeten J**. HIV-1 subtype C is not associated with higher viremia during early infection compared to other subtypes in an African cohort. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 549.
88. Murnane P, Hughes J, Celum C, Lingappa J, Mugo N, Magaret A, Wald A, Kiarie J, Farquhar C, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Using plasma HIV RNA levels to guide ART initiation to avert HIV transmissions. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 648.
89. Mujugira A, **Baeten J**, Donnell D, Cohen C, Katabira E, Tumwesigye E, Wangisi J, Brantley J, Celum C; Partners PrEP Study Team. Barriers to ART initiation among HIV-1+ individuals: East Africa. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 649.
90. Barnabas R, van Rooyen H, Joseph P, Phakathi Z, Krows M, Hong T, **Baeten J**, Celum C. Home point-of-care CD4 test provides accurate enumeration of CD4 count: South Africa. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 687.
91. Ndase P, Celum C, Donnell D, Farquhar C, Fife K, Ronald A, Coombs R, Kidoguchi L, **Baeten J**; Partners PrEP Study Team. Frequency of false positive HIV rapid tests in a cohort of men and women receiving PrEP—implications for programmatic roll-out: Kenya and Uganda. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1058.
92. Mugo N, Celum C, Donnell D, Campbell J, Bukusi E, John-Stewart G, Kiarie J, Were E, Thomas K, **Baeten J**; Partners PrEP Study Team. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1060.
93. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, **Baeten J**. Preferences for and willingness to use ARV-based HIV-1 prevention strategies among HIV-1 serodiscordant couples: Kenya. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1065.
94. Bangsberg D, Haberer J, Psaros C, **Baeten J**, Katabira E, Tumwesigye E, Ware N, Thomas K, Celum C, Safren S. High adherence and high effectiveness observed in HIV discordant couples: Partners PrEP Study, adherence monitoring and counseling sub-study. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1067.
95. Alsallaq R, **Baeten J**, Hughes J, Abu-Raddad L, Celum C, Hallett T. Modeling the potential impact of a combination prevention package based on community-wide HIV testing: KwaZulu-Natal, South Africa. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1079.
96. Haberer J, Psaros C, **Baeten J**, Katabira E, Tumwesigye E, Ronald A, Thomas K, Donnell D, Celum C, Safren S, Bangsberg D. High adherence to oral PrEP is associated with lack of infections in an ancillary study of objective adherence monitoring and counseling among HIV discordant couples in Partners PrEP Study. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1067.
97. Kahle E, Hughes J, Lingappa J, John-Stewart G, Nakku-Joloba E, Njuguna S, Bukusi E, Manongi R, Celum C, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. An empiric risk-scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March

5-8, 2012. Abstract 1102.

98. Laeyendecker O, Brookmeyer R, Mullis C, Donnell D, Lingappa J, Celum C, **Baeten J**, Campbell M, Quinn T, Eshleman S; Partners in Prevention HSV/HIV Transmission Study Team. Specificity of 4 laboratory approaches to determine cross-sectional HIV incidence: analysis of samples from adults with known non-recent HIV infection: 5 African countries. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1111.
99. van Rooyen H, Phakathi Z, Krows M, Hong T, Barnabas R, **Baeten J**, Celum C. High testing uptake and linkages to HIV treatment through home-based HIV counseling and testing and facilitated referral: KwaZulu-Natal, South Africa. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, March 5-8, 2012. Abstract 1135.
100. Ndase P, Mugo N, Campbell J, Wangisi J, Were E, John-Stewart G, Ronald A, Cohen CR, Celum C, **Baeten J**; Partners PrEP Study Team. Discontinuation of a placebo arm of a randomized trial in response to a positive interim efficacy result: the Partners PrEP Study. Microbicides 2012, Sydney, Australia, April 15-18, 2012.
101. Kahle E, Kashuba A, **Baeten J**, Delany S, Donnell D, John-Stewart G, Mujugira A, Mugo N, Celum C, Lingappa J. Unreported antiretroviral use by HIV-1 infected members of HIV-1 serodiscordant couples enrolling in an HIV-1 prevention clinical trial. Microbicides 2012, Sydney, Australia, April 15-18, 2012.
102. Mugo N, Heffron R, **Baeten J**, Ngure K, Celum C, Mburu S, Lingappa J. Are HIV risk reduction behavioral adaptations among HIV-1 serodiscordant couples sustainable beyond study participation? Microbicides 2012, Sydney, Australia, April 15-18, 2012.
103. Donnell D, **Baeten J**, Hendrix C, Bumpus N, Bangsberg D, Haberer J, Mujugira A, Celum C; Partners PrEP Study Team. Changes in detectable plasma levels over time in a pre-exposure prophylaxis clinical trial: the Partners PrEP Study. Microbicides 2012, Sydney, Australia, April 15-18, 2012.
104. Ngure K, Heffron R, Mugo N, Celum C, Cohen C, Odoyo J, Rees H, Kiarie J, Were E, **Baeten J**. Contraceptive method and pregnancy incidence among African women in HIV-1 serodiscordant partnerships. Microbicides 2012. Sydney, Australia, 15-18 April 2012. Abstract P130.
105. Chaturvedula A, Celum C, **Baeten J**, Donnell D, Bangsberg D, Haberer J, Mujugira A, Hendrix C. Development of population pharmacokinetic model of model for Tenofovir using sparsely sampled subject data. 21st Annual Meeting of Population Approach Group Europe, Venice, Italy, June 5-8, 2012. Abstract 2305.
106. Haberer J, **Baeten J**, Celum C, Katabira E, Ronald A, Tumwesigye E, Thomas K, Donnell D, Bangsberg D. High adherence among HIV-1 serodiscordant couples in the Partners PrEP Ancillary Adherence Study. 7th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 3-5, 2012. Abstract 80026.
107. Curran K, Mugo N, Kurth A, Ngure K, Heffron R, Celum C, **Baeten J**. A pilot study of daily short message service (SMS) surveys of sexual behavior and PrEP use among Kenyan HIV-1 serodiscordant couples. 7th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 3-5, 2012. Abstract 80028.
108. Psaros C, Haberer J, Thomas K, Katabira E, Ronald A, Tumwesigye E, Mugwanya K, Kintu A, Enyakoit M, Donnell D, **Baeten J**, Celum C, Bangsberg D, Safren S. Evaluation and process outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV-serodiscordant couples in Uganda. 7th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 3-5, 2012. Abstract 80031.
109. Ngure K, **Baeten J**, Mugo N, Curran K, Vusha S, Heffron R, Celum C, Shell-Duncan B. 'I feared. My intention was a child but I was very afraid.': fertility intentions and HIV-1 risk perception among HIV-1

- serodiscordant couples in Kenya. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract MOPE313.
110. Kahle E, Campbell M, Lingappa J, Donnell D, Celum C, Kapiga S, Ondondo R, Mugo N, Mujugira A, Fife K, Mullins J, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. HIV-1 subtype C is not associated with higher risk of heterosexual transmission: a multinational study among African HIV-1 serodiscordant couples. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract TUAC0101.
 111. Kahle E, Donnell D, Hughes J, Thomas K, John-Stewart G, Nakku-Joloba E, Bukusi E, Lingappa J, Celum C, **Baeten J**; Partners PrEP Study Team. PrEP has high efficacy for HIV-1 prevention among higher-risk HIV-1 serodiscordant couples: a subgroup analysis from the Partners PrEP Study. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract TUAC0102.
 112. van Rooyen H, Barnabas R, Pakathi Z, Joseph P, Krows M, Hong T, **Baeten J**, Celum C. High testing uptake and linkages to HIV treatment through home-based HIV counseling and testing and facilitated referral in KwaZulu-Natal, South Africa. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract TUPE756.
 113. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs R, **Baeten J**; Partners in Prevention HSV/HIV Transmission Study Team. Association of injectable contraception and risk of HIV-1 acquisition in women in HIV-1 serodiscordant partnerships: persistence of effect in multiple sensitivity analyses. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract WEAC0202.
 114. Barnabas RV, van Rooyen H, **Baeten JM**, Phakathi Z, Joseph P, Krows M, Hong T, Hughes JP, Celum. Significant decrease in community viral load and increase in proportion with suppressed viral load six months after a program of home-based HIV counseling and testing and facilitated referral to HIV care in KwaZulu-Natal, South Africa. XIX International AIDS Conference, Washington, D.C., USA, July 22-27, 2012. Abstract LBPE34.
 115. Murnane P, Celum C, Donnell D, Bukusi E, Mugo N, Tappero J, Kahle E, Mujugira A, Thomas KT, and **Baeten J**; Partners PrEP Study Team. PrEP efficacy among women in the Partners PrEP Study. 2012 CFAR Joint Symposium on HIV Research in Women, Providence, Rhode Island, USA, September 18, 2012. Abstract A-9.
 116. Barnabas R, **Baeten J**, Lingappa J, Thomas K, Hughes J, Delany-Moretlwe S, Gray G, Ronald A, Wald A, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir prophylaxis reduces the incidence of herpes among HIV+ individuals: result of a randomized clinical trial. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 868.
 117. Celum C, Morrow R, Donnell, D, Hong T, Fife K, Nakku-Joloba E, Mujugira A, **Baeten J**; Partners PrEP Study Team. Daily oral tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis and prevention of herpes simplex virus type 2 acquisition among heterosexual men and women. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 999.
 118. Murnane P, Celum C, Kahle E, Donnell, D, Bukusi E, Mugo N, Mujugira A, Thomas K, **Baeten J**; Partners PrEP Study Team. Daily oral pre-exposure prophylaxis is highly effective among subsets of highest-risk participants: Partners PrEP Study. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1000.
 119. **Baeten J**, Murnane P, Mugo N, Katabira, E, Heffron R, Mujugira A, Donnell, D, Celum C; Partners PrEP Study Team. When to stop pre-exposure prophylaxis: a prospective analysis of discontinuation of sexual activity and initiation of ART among HIV serodiscordant couples. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1002.

121. Heffron R, Ngure K, Mugo N, Celum C, Curran K, Kurth A, **Baeten J**. Preferred pre-exposure prophylaxis dosing regimens and sex planning among Kenyan HIV-1 serodiscordant couples. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1003.
122. Curran K, Mugo N, Kurth A, Ngure K, Heffron R, Celum C, **Baeten J**. Daily assessment of sexual activity and pre-exposure prophylaxis use among Kenyan HIV serodiscordant couples. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1004.
123. Mujugira A, Heffron R, Celum C, Mugo N, Nakku-Joloba E, **Baeten J**. Fertility intentions and interest in early ART among East African HIV+ individuals in HIV serodiscordant partnerships. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1005.
124. van Rooyen H, Barnabas R, Tumwesigye E, Humphries H, Tumwebaze H, Joseph P, Krows M, Murnane P, **Baeten J**, Celum. Characteristics and testing uptake of heterosexual couples identified through home-based testing and facilitated referral: South Africa and Uganda. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1065.
125. Ngure K, Heffron R, Mugo N, Celum C, Curran K, Kurth A, **Baeten J**. Fertility intentions and interest in peri-conception HIV-1 risk reduction strategies among HIV-1 serodiscordant couples: Kenya. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, March 3-6, 2013. Abstract 1087.
126. Curran K, Shell-Duncan B, Mugo N, Chabeda S, Ngure K, Heffron R, Celum C, **Baeten J**. "If I am given ARVs I will think I am nearing the grave": HIV serodiscordant couples' attitudes, motivations, and concerns regarding early initiation of antiretroviral therapy in Kenya. 3rd International HIV Treatment as Prevention Workshop: From Evidence to Action, Vancouver, Canada, April 22-25, 2013. Abstract 4019.
127. Barnabas R, van Rooyen H, Tumwesigye E, Murnane P, Humphries H, Turyamureeba B, Krows M, Hughes J, **Baeten J**, Celum C. Uptake of ART is lower among HIV-infected persons with higher CD4 counts despite engagement in care in KwaZulu-Natal, South Africa, and Mbarara district, Uganda. 3rd International HIV Treatment as Prevention Workshop: From Evidence to Action, Vancouver, Canada, April 22-25, 2013. Abstract 4107.
128. Barnabas R, Tumwesigye E, van Rooyen H, Murnane P, Humphries H, Turyamureeba B, Krows M, Hughes J, **Baeten J**, Celum C. Community-based HCT studies demonstrate high uptake of HIV testing, successful linkages to care & viral load suppression in South Africa & Uganda. 3rd International HIV Treatment as Prevention Workshop: From Evidence to Action, Vancouver, Canada, April 22-25, 2013.
129. Barnabas R, Tumwesigye E, van Rooyen H, Murnane P, Turyamureeba B, Humphries H, Krows M, Hughes J, **Baeten J**, Celum C. Study updates: combination trials in South Africa and Uganda. 3rd International HIV Treatment as Prevention Workshop: From Evidence to Action, Vancouver, Canada, April 22-25, 2013. Abstract.
130. Mujugira A, Celum C, Thomas K, Farquhar C, Mugo N, Katabira E, Bukusi E, Tumwesigye E, **Baeten J**; Partners PrEP Study Team. Delay in antiretroviral therapy initiation is common among East African HIV-1-infected individuals in serodiscordant partnerships. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, June 30 - July 3, 2013. Abstract MOAC0202.
131. Smith J, Heffron R, Celum C, **Baeten J**, Hallett T. Could misreporting of condom use explain the apparent association between injectable hormonal contraceptives and HIV acquisition risk. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, June 30 - July 3, 2013. Abstract MOPE125.
132. Mugo N, Hong T, Celum C, Donnell D, Bukusi E, Were E, John-Stewart G, **Baeten J**; Partners PrEP Study Team. Pregnancy incidence and birth outcomes among African women in a clinical trial of pre-

exposure prophylaxis: the Partners PrEP Study. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, June 30 - July 3, 2013. Abstract WEAC0101.

133. Mugwanya KK, Donnell D, Celum C, Mugo N, Thomas KK, Ngure K, Ndase P, Katabira E, **Baeten JM**. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: post-unblinding analysis of the Partners PrEP Study. STI & AIDS World Congress 2013, Vienna, Austria, July 14-17, 2013. Abstract O11.2.
134. Heffron RA, Donnell D, Mugo N, Celum C, Rees H, Ngure K, Were E, Kiarie J, **Baeten JM**. Effect of pregnancy on HIV-1 disease progression among antiretroviral-naïve HIV-1 infected women. STI & AIDS World Congress 2013, Vienna, Austria, July 14-17, 2013. Abstract P3.200.
135. Ying R, Celum C, **Baeten J**, Murnane P, Hong T, Krows M, van Rooyen M, Humphries H, Hughes JP, Barnabas R. Pre-exposure prophylaxis (PrEP) is estimated to be a cost-effective addition to antiretroviral therapy (ART) for HIV prevention in a generalized epidemic setting. STI & AIDS World Congress 2013, Vienna, Austria, July 14-17, 2013. Abstract P3.226.
136. Celum C, Morrow R, Donnell D, Hong T, Thomas K, Fife K, Nakku-Joloba E, Mujugira A, **Baeten J**. Daily oral emtricitabine/tenofovir pre-exposure prophylaxis and prevention of HSV-2 acquisition among heterosexual men and women. STI & AIDS World Congress 2013, Vienna, Austria, July 14-17, 2013. Abstract P3.370.
137. **Baeten J**. PrEP and treatment as prevention for HIV: finding the balance. STI & AIDS World Congress 2013, Vienna, Austria, July 14-17, 2013. Abstract PL05.1.
138. Ying R, Celum C, **Baeten J**, Lingappa JR, Thomas KK, Murnane P, Krows M, van Rooyen H, Hughes JP and Barnabas R. Expanding antiretroviral therapy eligibility by HIV viral load criteria is a potentially effective and cost-effective strategy for HIV prevention. STD & AIDS Symposium, Seattle, Washington, USA, October 29, 2013.
139. Ying R, Celum C, **Baeten J**, Lingappa J, Thomas K, Murnane P, Krows M, van Rooyen H, Hughes JP and Barnabas R. Antiretroviral therapy (ART) initiation by HIV viral load is estimated to be more cost-effective than by CD4 T-cell count in a generalized epidemic setting. Epidemics 4, Amsterdam, Netherlands, November 19-22, 2013. Abstract P1.108.
140. Barnabas R, van Rooyen H, Tumwesigye E, Humphries H, Turyamureeba B, Murnane P, Hughes JP, **Baeten J**, Celum C. Community-based HCT studies demonstrate high up-take of HIV testing and successful linkages to care in South Africa & Uganda. 17th International Conference on AIDS and STIs in Africa (ICASA), Cape Town, South Africa, December 7-11, 2013. Abstract.
141. **Baeten J**, Donnell D, Ndase P, Mugo N, Celum C; Partners PrEP Study Team. Single agent TDF versus combination FTC/TDF PrEP among heterosexual men and women. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 43.
142. Barnabas R, van Rooyen H, Tumwesigye E, Krows M, Murnane P, Humphries H, Turyamureeba B, Hughes JP, **Baeten J**, Celum C. Community HIV testing and linkage to care reduces population viral load in South Africa and Uganda. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 148.
143. Kahle E, Bolton M, Hughes J, Donnell D, Celum C, Lingappa J, Ronald A, de Bruyn G, McElrath J, **Baeten J**. Immune activation and risk of HIV-1 transmission among HIV-1 serodiscordant couples. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 271.
144. Lehman D, **Baeten J**, McCoy C, Weis JF, Peterson D, Celum C, Mugo N, Overbaugh J, Matsen F; Partners PrEP Study Team. PrEP exposure and the risk of low-frequency drug resistance. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6,

145. Masese L, **Baeten JM**, Richardson B, Graham SM, Bukusi E, Shafi J, Jaoko W, Kiarie J, McClelland RS. Changes in the contribution (PAR%) of STIs to HIV acquisition among Kenyan FSWs from 1993 to 2012. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 944.
146. Heffron R, Celum C, Mugo N, Katabira E, Bukusi E, Tumwesigye E, Haberer J, **Baeten J**, Partners Demonstration Project Study Team. High initiation of PrEP and ART in a demonstration project among African HIV-discordant couples. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 949.
147. Heffron R, Mugo N, Were E, Kiarie J, Bukusi E, Mujugira A, Donnell D, Ronald A, Celum C, **Baeten J**; Partners PrEP Study Team. PrEP is efficacious for HIV prevention among women using DMPA for contraceptions. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 950.
148. Matthews L, Heffron R, Mugo N, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, **Baeten JM**. Partners PrEP Study Team. High medication adherence during periconception periods among HIV-1 uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 955.
149. Murnane PM, Heffron RA, Celum C, Bukusi E, Donnell D, Kiarie J, Mugo N, Ronald A, Were E, **Baeten J**; Partners PrEP Study Team. PrEP does not diminish the pregnancy prevention effectiveness of hormonal contraception. CROI 2014: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. Abstract 957.
150. Ying R, Celum C, **Baeten J**, Murnane P, Hong T, Krows M, van Rooyen H, Humphries H, Hughes JP, Barnabas R. Pre-exposure prophylaxis for young women with concomitant partner testing can cost-effectively reduce HIV incidence in KwaZulu-Natal, South Africa. 4th International HIV Treatment as Prevention Workshop (TasP), Vancouver, Canada, April 1-4, 2014. Abstract 5033.
151. Khanna A, Roberts ST, Cassels S, **Baeten J**, Murnane P, Celum C, Barnabas R. Lifelong antiretroviral therapy for prevention of mother to child transmission of HIV has potential to decrease adult HIV incidence due to sexual transmission. 4th International HIV Treatment as Prevention Workshop (TasP), Vancouver, Canada, April 1-4, 2014. Abstract 6014.
152. Irungu E, Heffron R, Mugo N, Ngure K, Katabira E, Nakku-Joloba E, Bulya N, Bukusi E, Odoyo J, Asiimwe S, Tumwesigye E, Celum C, **Baeten J**; Partners Demonstration Project Team. Evaluation of a risk score to identify higher-risk HIV-1 serodiscordant couples for evaluation of antiretroviral-based HIV-1 prevention interventions. Fifth Annual Consortium of Universities for Global Health Conference, Washington, DC, USA, May 10-12, 2014. Poster PO01.080.
153. Haberer J, **Baeten J**, Heffron R, Mugo N, Katabira E, Ngure K, Njuguna N, Muwonge T, Kidoguchi L, Ng C, Bangsberg D. Self-reported adherence to pre-exposure prophylaxis (PrEP) and sexual behavior by text messaging: preliminary findings from the Partners Mobile Adherence to PrEP Study. 9th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 8-10, 2014. Abstract 316.
154. Haberer J, **Baeten J**, Heffron R, Donnell D, Mugo N, Katabira E, Bukusi E, Asiimwe S, Thomas K, Kidoguchi L, Celum C, Bangsberg D. Adherence to pre-exposure prophylaxis in the Partners Demonstration Project: preliminary findings. 9th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 8-10, 2014. Abstract 317.
155. Curran K, Mugo N, Kurth A, Ngure K, Heffron R, Donnell D, Celum C, **Baeten J**. Daily short message service surveys detect greater HIV risk behavior than monthly clinic questionnaires in Kenya. 9th

International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 8-10, 2014. Abstract 382.

156. Ware N, Pisarski E, Haberer J, Wyatt M, Tumwesigye E, **Baeten J**, Celum C, Bangsberg D. Lay social resources for support of adherence to antiretroviral prophylaxis for HIV prevention among serodiscordant couples in sub-Saharan Africa: a qualitative study. 9th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, June 8-10, 2014. Abstract 468.
157. Murnane P, Brown E, Donnell D, Mugo N, Mujugira A, Celum C, **Baeten J**; Partners PrEP Study Team. Estimating the causal effect of PrEP for HIV-1 prevention. Society for Epidemiologic Research (SER) Annual Meeting, Seattle, Washington, USA, June 24-27, 2014. Abstract 233-S.
158. Pintye J, **Baeten J**, Manhart L, Celum C, Ronald A, Mugo N, Mujugira A, Cohen C, Were E, Bukusi E, Kiarie J, Heffron R. Male circumcision and the incidence of syphilis acquisition among male and female partners of HIV-1 serodiscordant heterosexual African couples: a prospective study. AIDS 2014: 20th International AIDS Conference, Melbourne, Australia, July 20-25, 2014. Abstract MOPDC0103.
159. Curran K, Johnson C, Ngure K, Mugo N, **Baeten J**, Heffron R, Koechlin F, O'Reilly K, Baggaley R. The potential role of HIV self-testing within pre-exposure prophylaxis implementation. AIDS 2014: 20th International AIDS Conference, Melbourne, Australia, July 20-25, 2014. Abstract TUAC0101.
160. Ngure K, Heffron R, Mugo N, Celum C, Cohen CR, Bukusi EA, Kiarie J, Were E, Mujugira A, **Baeten JM**. Intravaginal washing practices and the risk of BV among Kenya and Uganda HIV-1 uninfected and infected women. AIDS 2014: 20th International AIDS Conference, Melbourne, Australia, July 20-25, 2014. Abstract TUPE105.
161. Heffron R, Thomson K, Mugo N, Bukusi E, Ngure K, Celum C, **Baeten J**; Partners Demonstration Project team. Knowledge and willingness of African women in HIV-1 discordant partnerships to use safer conception strategies during peri-conception periods. Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting, Stowe, Vermont, USA, August 7-9, 2014. Abstract 20.
162. Mugo NR, Eckert L, Celum C, **Baeten J**, Galloway D, Mwaniki L, Wamalwa D, Ngure K, Irungu E, Wald A. Quadrivalent HPV vaccine is safe and well-tolerated among HIV-infected pre-adolescent girls and boys in Kenya. 29th International Papillomavirus Conference (HPV 2014), Seattle, Washington, USA, August 21-15, 2014. Abstract BP.PP02.08.
163. Lu Y, Goti V, Chaturvedula A, Haberer J, Fossler M, Sale M, Bangsberg D, **Baeten J**, Celum C, Hendrix C. Population pharmacokinetics of tenofovir in HIV uninfected members of serodiscordant couples and effect of dose reporting methods: an analysis from Partners PrEP Study. American Conference on Pharmacometrics (ACOP5), Las Vegas, Nevada, USA, October 14-16, 2014. Abstract W-003.
164. Madrasi K, Chaturvedula A, Haberer J, Sale M, Fossler M, Bangsberg D, **Baeten J**, Celum C, Hendrix C. Markov mixed effects modeling of adherence using MEMS dosing records from Partners PrEP Ancillary Adherence substudy. American Conference on Pharmacometrics (ACOP5), Las Vegas, Nevada, USA, October 14-16, 2014. Abstract M-032.
165. Pattachini L, **Baeten JM**, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Bukusi E, Ronald A, Mugo N, Lingappa JR, Celum C, McElrath MJ, Lund JM; Partners PrEP Study Team. HIV-specific T and NK-cell responses do not correlate with protection from sexual acquisition of HIV. HIV Research for Prevention (HIV R4P) Meeting, Cape Town, South Africa, October 28-31, 2014. Abstract P03.01.
166. Ngure K, Heffron R, Mugo N, Irungu E, Njuguna N, Mwaniki L, Thompson K, Celum C, **Baeten JM**. Uptake of HIV self-testing among people receiving PrEP in Kenya. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract OA27.02.
167. Irungu EM, Heffron R, Mugo N, Ngure K, Katabira E, Bulya N, Bukusi E, Odoyo J, Asimwe S, Tindimwebwa E, Donnell D, Celum C, **Baeten JM**; Partners Demonstration Project Team. Evaluation of

a risk score tool to identify higher-risk HIV-1 serodiscordant couples for antiretroviral-based HIV-1 prevention. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract OA28.02.

168. Schwartz K, Ndase P, Torjesen K, Mayo A, Scheckter R, van der Straten A, Soto-Torres L, Palanee T, **Baeten J**. Supporting participant adherence through structured engagement activities in the MTN-020 (ASPIRE) trial. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract PD01.01.
169. Mackelprang RD, Birsie K, Emond MJ, Burgener A, Ball B, **Baeten J**, Celum C, Cohen CR, Mugo NR, Lingappa JR; Partners PrEP Study Team. Genital proteome correlates of highly HIV-1 exposed uninfected African women. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract PD02.01.
170. Scheckter R, Schwartz K, Mayo A, **Baeten J**, Palanee T, Soto-Torres L, Torjensen K. Managing communication and facilitating the exchange of ideas in a large, multi-site clinical trial: experiences from the ASPIRE study. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P02.01
171. Pattacini L, **Baeten JM**, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Bukusi E, Ronald A, Mugo N, Lingappa JR, Celum C, McElrath MJ, Lund JM; Partners PrEP Study Team. HIV-specific T nad NK-cell responses do not correlate with protection from sexual acquisition of HIV. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P03.01.
172. Sharma M, van Rooyen H, Celum C, **Baeten J**, Levin C, Barnabas R. The cost of community based HIV counseling and testing and linkage to care in rural South Africa: estimates from the Linkages randomized controlled trial. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P09.17LB.
173. Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Kiarie J, Ronald A, **Baeten JM**; Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis and risk of decreased glomerular filtration rate among HIV uninfected men and women. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P20.03.
174. Ngure K, Curran K, Vusha S, Ngutu M, Mugo N, Celum C, Shell-Duncan B, Heffron R, **Baeten JM**. Following the doctor's advice: experiences of HIV serodiscordant couples enrolled in a PrEP demonstration project in Kenya. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P46.06.
175. Mujugira A, Celum C, Ronald A, Mugo N, **Baeten JM**; Partners PrEP Study Team. Frequency of achieving viral suppression among HIV-infected persons in serodiscordant partnerships initiating antiretroviral therapy. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P52.06.
176. Palanee T, Schwartz K, Brown E, Govender V, Mgodhi N, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker LG, Gaffoor Z, Jeenarain N, Naidoo S, Martinson F, Philip J, Pather A, Makanani B, Soto-Torres L, **Baeten J**, on behalf of the ASPIRE Study Team. Baseline characteristics of HIV-1 negative women enrolled into a clinical trial of dapivirine vaginal ring for HIV-1 prevention. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P53.03.
177. Heffron R, Celum C, Mugo N, Katabira E, Bukusi E, Asiimwe S, Ngure K, Bulya N, Odoyo J, Tindimwebwa E, Donnell D, Haberer J, Kidoguchi L, Morton J, **Baeten JM**; Partners Demonstration Project Team. High initiation and adherence among high risk African HIV discordant couples in a demonstration project of PrEP and ART for HIV prevention. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract OA28.01.
178. Pattacini L, Murnane PM, **Baeten JM**, Fluharty TR, Thomas KK, Bukusi E, Katabira E, Mugo N, Donnell

- D, Lingappa JR, Celum C, Marzinke M, McElrath MJ, Lund JM; Partners PrEP Study Team. Pre-exposure prophylaxis does not enhance HIV-specific T-cell responses. HIV Research for Prevention (R4P) 2014, Cape Town, South Africa, October 28-31, 2014. Abstract P24.07.
179. Lehman DA, **Baeten JM**, McCoy C, Weis JF, Warth C, Celum C, Mugo N, Overbaugh J, Matsen FA; Partners PrEP Study Team. Resistance is prevalent during acute HIV infection without evidence of drug selection. XXIV International HIV Drug Resistance Workshop. Seattle, Washington, USA, February 21-22, 2015. Abstract 80.
 180. Weis JF, **Baeten JM**, Kanthula R, McCoy C, Frenkel L, Mugo N, Matsen FA, Overbaugh J, Celum C, Lehman DA. PrEP-selected drug resistance fades by six months following drug cessation. XXIV International HIV Drug Resistance Workshop. Seattle, Washington, USA, February 21-22, 2015. Abstract 36.
 181. Pattacini L, **Baeten JM**, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Mugo N, Lingappa JR, Celum C, Lund JM. Increased levels of regulatory T-cells correlate with protection from HIV infection. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 290.
 182. Weis JF, **Baeten JM**, Kanthula R, McCoy C, Frenkel L, Mugo N, Matsen FA, Overbaugh J, Celum C, Lehman DA. PrEP-selected Drug Resistance Fades by Six Months Following Drug Cessation. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 983.
 183. **Baeten JM**, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, Asimwe S, Haberer J, Donnell D, Celum C; Partners Demonstration Project Team. Near elimination of HIV transmission in a demonstration project of PrEP and ART. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 24.
 184. Heffron R, Ngure K, Semiyaga NB, Odoyo J, Tindimwebwa E, Morton J, Kidoguchi L, Marzinke M, Celum C, **Baeten JM**; Partners Demonstration Project Team. Sustained PrEP use among high-risk African HIV serodiscordant couples participating in a PrEP demonstration project. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 969.
 185. Muganzi DC, Boum II Y, Musinguzi N, Ronald A, Celum C, **Baeten J**, Bangsberg DR, Haberer J for the Partners PrEP Ancillary Adherence Study Team. Comparison of adherence measures in a clinical trial of pre-exposure prophylaxis. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 976.
 186. Mujugira A, Thomas KK, Celum C, Donnell D, Farquhar C, Bukusi EA, **Baeten JM**, and the Partners in PrEP Study Team. HIV-1 transmission risk persists during the first 6 months of antiretroviral therapy. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 989.
 187. Roberts S, Celum C, Mugo N, Haberer J, Cohen CR, Irungu E, Kiarie J, Were E, **Baeten JM**; Partners PrEP Study Team. Intimate partner violence is associated with low PrEP adherence in African women. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 980.
 188. Thomson K, Celum C, Mujugira A, Ndase P, **Baeten J**, Hendrix C, Marzinke M, Ronald A, Haberer J, Bangsberg D. Medication sharing among African HIV serodiscordant couples enrolled in a PrEP trial. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 988.
 189. Ying R, Heffron R, **Baeten J**, Celum C, Katabira E, Bulya N, Barnabas R. Cost-effectiveness of pre-exposure prophylaxis for high-risk HIV discordant couples. CROI 2015: Conference on Retroviruses and

190. Smith J, Sharma M, Levin C, **Baeten J**, van Rooyen H, Celum C, Hallett T, Barnabas R. Community-based strategies to strengthen the continuum of HIV care are cost-effective. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 1111.
191. Mugwanya K, Wyatt C, Celum C, Donnell D, Mugo N, Kiarie J, Ronald A, **Baeten J**. Reversibility of kidney function decline in HIV-1 uninfected men and women using preexposure prophylaxis. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 981.
192. Ying R, Heffron R, **Baeten J**, Celum C, Barnabas R, Katabira E, Bulya N. Cost-effectiveness of preexposure prophylaxis for high-risk HIV-discordant couples. CROI 2015: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, February 23-26, 2015. Abstract 1106.
193. Pyra M, Heffron R, Mugo NR, Nanda K, Thomas KK, Celum C, Kourtis AP, **Baeten JM**, Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams. Effectiveness of contraception for HIV-infected women using antiretroviral therapy: combined data from 3 longitudinal studies. 8th IAS Conference on HIV Pathogenesis, Treatment, & Prevention, Vancouver, Canada, July 19-22, 2015. Abstract MOPDB0103.
194. Njuguna N, Mugo NR, Ngure K, Irungu E, Sambu C, Maronga C, Gakuo S, **Baeten J**, Heffron R. Text messages increased HIV testing among young women in Kenya: a pilot study. 8th IAS Conference on HIV Pathogenesis, Treatment, & Prevention, Vancouver, Canada, July 19-22, 2015. Abstract MOPEC424.
195. Heffron R, Thomson K, Celum C, Mugo N, Katabira E, Bukusi E, Asiimwe, Ngure K, Bulya N, Odoyo J, Tindimwebwa E, Donnell D, **Baeten J**, Partners Demonstration Project Team. Fertility intentions, pregnancy and PrEP use in African HIV serodiscordant couples. 8th IAS Conference on HIV Pathogenesis, Treatment, & Prevention, Vancouver, Canada, July 19-22, 2015. Abstract TUPEC511.
196. Ngure K, Heffron R, Hong T, Mugo N, Bukusi E, Ndase P, Mujugira A, Muwonge T, Celum C, **Baeten JM**. Discordance in unprotected sex reporting among African HIV serodiscordant couples. 8th IAS Conference on HIV Pathogenesis, Treatment, & Prevention, Vancouver, Canada, July 19-22, 2015. Abstract MOPEC402.
197. Barnabas R, van Rooyen H, Tumwesigye E, Brantley J, **Baeten J**, van Heerden A, Turyamureeba B, Joseph P, Krows M, Hughes J, Celum C. Community-based HIV testing and linkage effectively delivers combination HIV prevention: results from a multisite randomized trial. 8th IAS Conference on HIV Pathogenesis, Treatment, & Prevention, Vancouver, Canada, July 19-22, 2015. Abstract MOAC0105LB.
198. Njuguna N, Mugo N, Ngure K, Irungu E, Sambu C, Maronga C, Gakuo S, **Baeten J**, Heffron R. Text messages increase HIV testing among young women in Kenya: a pilot study. IAS 2015: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada, July 19-22, 2015. Abstract MPOEC424.

16. Invited Presentations

1. Vitamin A supplementation and HIV-1 shedding in women: results of a randomized clinical trial. University of Washington STD Conference. Seattle, Washington, USA, October 2001.
2. Effect of contraceptive method on the natural history of HIV. National Institutes of Health. Fertility Regulation and Systemic Hormones in HIV-Infected and At-Risk Women. McLean, Virginia, USA, January 2003.

3. The influence of vitamin A and hormonal contraception on HIV transmission and disease progression in women. 10th Conference on Retroviruses and Opportunistic Infections. Symposium: HIV Infection in Women. Boston, Massachusetts, USA, February 2003.
4. Hypothesized mechanisms by which hormonal contraception might influence HIV-1 transmission. Gynuity Health Projects. Hormonal Contraception and HIV Transmission: Links? Mechanisms? Implications? New York, New York, USA, May 2005.
5. Epidemiology of HIV-1 among adolescents and young adults. AIDS Vaccine 2005. Symposium: Inclusion of Adolescents in HIV Vaccine Trials. Montreal, Canada, September 2005.
6. Hormonal contraception and HIV-1: studies from Mombasa, Kenya. Brigham and Women's Hospital Infectious Disease Conference. Boston, Massachusetts, USA, November 2005.
7. New biomedical approaches for HIV prevention in women. 34th Annual Scientific Meeting of the Infectious Disease Society for Obstetrics and Gynecology. HIV Prevention Strategies Symposium. Boston, Massachusetts, USA, August 2007.
8. Herpes simplex virus suppressive treatment decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 co-infected women and men: Peru cross-over trials. WHO consultation to update STI guidelines. Montreux, Switzerland, April 2008.
9. Pre-exposure prophylaxis for HIV prevention: current studies and potential implementation. Public Health – Seattle & King County. Seattle, Washington, USA, December 2008.
10. Pre-exposure prophylaxis for HIV prevention. University of Washington AIDS Clinical Conference. Seattle, Washington, USA, January 2009.
11. Pre-exposure prophylaxis for HIV prevention. I-TECH HIV/AIDS Clinical Seminar Series/ I-TECH Distance Learning Initiative. Seattle, Washington, USA, March 2009.
12. HSV-2 suppression to prevent HIV acquisition: evidence, intervention, & lessons learned. Bill & Melinda Gates Foundation. Female Genital Schistosomiasis/HIV Consultation. Seattle, Washington, USA, April 2009.
13. Partners PrEP Study: lessons learned. Microbicide Trials Network Annual Meeting. Arlington, Virginia, USA, April 2009.
14. The role of vaginal microflora in HIV risk and prevention. Office of AIDS Research Advisory Council, National Institutes of Health. Rockville, Maryland, USA, April 2009.
15. Contraception provision in the Partners PrEP Study. Global Campaign for Microbicides. Consultation on Family Planning and Contraception in HIV Prevention Trials. Arlington, Virginia, USA, April 2009.
16. Antiretroviral pre-exposure prophylaxis for HIV prevention: the Partners PrEP Study. University of Washington Global Infectious Disease Symposium. Seattle, Washington, USA, September 2009.
17. Partners PrEP Study. Alliance for Microbicide Development 12th Annual Meeting. Washington, DC, USA, October 2009.
18. Ongoing PrEP studies: timelines and lessons learned. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2009.
19. Pre-exposure prophylaxis for HIV prevention. Washington State Department of Health HIV Prevention Planning Group. Seattle, Washington, USA, January 2010.

20. Pre-exposure prophylaxis for HIV prevention. Fred Hutchinson Cancer Research Center Vaccine and Infectious Diseases Institute Seminar Series. Seattle, Washington, USA, February 2010.
21. Pre-exposure prophylaxis for HIV prevention. Department of Epidemiology Infectious Diseases Seminar Series, Harvard School of Public Health. Boston, Massachusetts, USA, March 2010.
22. State of the science. PrEP Delivery Working Group. Paris, France, March 2010.
23. Multicenter efficacy trial of antiretroviral prophylaxis among HIV discordant couples in East Africa. University of Washington Department of Epidemiology Seminar. Seattle, Washington, USA, May 2010.
24. Pre-exposure prophylaxis for HIV prevention. Kenyatta National Hospital Comprehensive Care Clinic Seminar. Nairobi, Kenya, June 2010.
25. Pre-exposure prophylaxis for HIV prevention. CDC-Kenya Seminar. Kisumu, Kenya, June 2010.
26. Antiretroviral medications and HIV prevention. Moi University Teaching and Referral Hospital Grand Rounds. Eldoret, Kenya, July 2010.
27. Update on PrEP trials. NIH/NIAID/NICHD consultation on pregnancy and microbicide research. Bethesda, Maryland, USA, November 2010.
28. Pre-exposure prophylaxis (PrEP) for HIV prevention. Public Health Seattle & King County Salon. Seattle, Washington, USA, February 2011.
29. Pre-exposure prophylaxis (PrEP) for HIV prevention: current science. Gay City Health Project Community Forum. Seattle, Washington, USA, April 2011.
30. Update on HIV prevention. 38th Annual Scientific Meeting of the Infectious Diseases Society for Obstetrics and Gynecology. Chicago, Illinois, USA, August 2011.
31. Antiretrovirals for HIV prevention. Harborview Medical Center Department of Medicine Science in Medicine series. Seattle, Washington, USA, August 2011.
32. The Partners PrEP Study. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2011.
33. MTN 020/ASPIRE. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2011.
34. Pre-exposure prophylaxis (PrEP) for HIV prevention. Northwest AIDS Education Training Center Continuing Medical Education dinner. Seattle, Washington, USA, October 2011.
35. Population selection for a potential randomized clinical trial of contraception and HIV acquisition risk. NIH-USAID-Bill and Melinda Gates Foundation meeting on hormonal contraception and HIV risk. Washington, DC, USA, December 2011.
36. Epidemiologic studies of the relationship between contraceptive use and HIV acquisition and transmission: what can we pursue in the near-term and what can we expect to learn? WHO Meeting on Hormonal Contraception and HIV Infection. Geneva, Switzerland, February 2012.
37. Hormonal contraception and risk of HIV transmission: implications and unknowns. Seattle STD/HIV Prevention Training Center Update on the Management of STDs and HIV Prevention. Seattle, Washington, USA, February 2012.
38. Contraception and HIV risk: evidence and unknowns. Microbicides Trials Network Annual Meeting.

Bethesda, Maryland, USA, February 2012.

39. MTN-020/ASPIRE. Microbicides Trials Network Annual Meeting. Bethesda, Maryland, USA, February 2012.
40. What can the twisted tale of PrEP results tell us? 19th Conference on Retroviruses and Opportunistic Infections. Symposium: Next Steps in Using ARV for Prevention. Seattle, Washington, USA, March 2012.
41. Advancing New Strategies for HIV Prevention: Antiretroviral Treatment, PrEP, and Combination Prevention, A Researcher's Perspective. amFAR/AVAC Capitol Hill briefing: Beginning to End the AIDS Epidemic: What's the Research Agenda? Washington, DC, USA, May 2012.
42. Pre-exposure prophylaxis (PrEP) for HIV prevention. Northwest AIDS Education and Training Center management training. Seattle, Washington, USA, May 2012.
43. Pre-exposure prophylaxis (PrEP) for HIV prevention. Project ECHO training. Seattle, Washington, USA, May 2012.
44. Antiretroviral-based HIV treatment and prevention strategies: advancing science into practice. Keynote Address: 7th International Conference on HIV Treatment and Prevention Adherence. Miami, Florida, USA, June 2012.
45. Pre-exposure prophylaxis (PrEP) for HIV prevention: efficacy, effectiveness, and impact. Workshop: Antiretroviral Therapy in Resource-Limited Settings: Progress and Evolving Challenges. XIX International AIDS Conference. Washington, DC, USA, July 2012.
46. Looking back, looking forward: what we know and don't know about oral PrEP and tenofovir gel for preventing HIV in women. Satellite: CHOICE MATTERS: expanding the method mix of ARV-based prevention for women in 2012 and beyond. XIX International AIDS Conference. Washington, DC, USA, July 2012.
47. Oral pre-exposure prophylaxis (PrEP) for HIV prevention: next steps. Plenary Lecture: AIDS Vaccine 2012. Boston, Massachusetts, USA, September 2012.
48. Pre-exposure prophylaxis (PrEP) for HIV: where have we been and where are we going? Symposium: What's New in Antiretroviral Therapy. 52nd Interscience Conference on Antimicrob Agents Chemother. . San Francisco, California, USA, September 2012.
49. Hormonal contraception and HIV acquisition risk: evidence and unknowns. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2012.
50. MTN 020/ASPIRE. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2012.
51. New strategies for HIV prevention in Africa: envisioning the end of AIDS? University of Washington Science In Medicine Lecture Series. Seattle, Washington, USA, October 2012.
52. Pre-exposure prophylaxis (PrEP) for HIV-1 prevention: moving science into practice. University of Washington Department of Medicine Grand Rounds. Seattle, Washington, USA, November 2012.
53. Antiretrovirals for HIV prevention. Stakeholder coordination meeting on harm reduction initiatives in Kenya. Nairobi, Kenya, November 2012.
54. New biomedical strategies for HIV prevention: where do we go from here? Seattle World AIDS Day Symposium, Seattle, Washington, USA, December 2012.

55. Contraception and HIV transmission: evidence, unknowns, implications. 3rd International Workshop on HIV & Women. Toronto, Canada, January 2013.
56. Update on the Partners PrEP Study and the Partners Demonstration Project. University of Nairobi STD/HIV Collaborative Group Meeting. Nairobi, Kenya, January 2013.
57. HIV prevention in Africa: from science to practice. University of Washington Medical Scientist Training Program. Seattle, Washington, USA, January 2013.
58. MTN 020/ASPIRE. Microbicides Trials Network Annual Meeting. Washington, DC, USA, February 2013.
59. Vaginal microbicides for HIV prevention. Be the Bridge Generation Meeting. Washington, DC, USA, February 2013.
60. Rationale for development of long-acting agents for HIV prevention. Long-acting Agents for HIV Treatment and Prevention: State of the Science and Implications for Adherence. Miami, Florida, June 2013.
61. PrEP and treatment as prevention: finding the balance. Plenary Lecture: STI & AIDS World Congress 2013. Vienna, Austria, July 2013.
62. Hormonal contraception and risk of HIV acquisition and transmission: evidence, unknowns, implications. University of Washington Andrology Research Group. Seattle, Washington, USA, September 2013.
63. PrEP implementation: one perspective. Controlling the HIV Epidemic with Antiretrovirals: From Consensus to Implementation. London, United Kingdom, September 2013.
64. A (potential) randomized clinical trial to assess the relative benefits and risks, including HIV acquisition, or different highly-effective contraceptive methods. Plenary Lecture: North American Forum on Family Planning. Seattle, Washington, USA, October 2013.
65. Update on PrEP for HIV prevention. Symposium Lecture: North American Forum on Family Planning. Seattle, Washington, USA, October 2013.
66. Monitoring adherence with PK data. Microbicides Trials Network Regional Meeting. Cape Town, South Africa, October 2013.
67. Antiretrovirals for HIV prevention: evidence, questions, and next steps. Grand Rounds: HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York City, New York, November 2013.
68. Update on pre-exposure prophylaxis (PrEP) for HIV prevention. Project ECHO. Seattle, Washington, USA, December 2013.
69. PEP and PrEP: are you ready? Planned Parenthood Medical Directors Council 10th Annual Update in Reproductive Health and Medical Leadership. Crested Butte, Colorado, USA, March 2014.
70. PrEP for HIV prevention. Public Health Seattle & King County STD Clinic. Seattle, Washington, USA, April 2014.
71. Antiretrovirals for HIV prevention: evidence and implementation. University of Washington Department of Global Health Faculty Research Seminar. Seattle, Washington, USA, April 2014.
72. Update on PrEP. University of Washington AIDS Clinical Conference. Seattle, Washington, USA, October 2014.
73. Advances in antiretroviral-based prevention. Plenary Lecture: HIV Research for Prevention (R4P). Cape

Town, South Africa, October 2014.

74. Advances in antiretroviral-based prevention. NEMUS Webinar Series, December 2014.
75. Global update on PrEP. Plenary lecture: University of Nairobi Collaborative Group Meeting. Nairobi, Kenya, January 2015.
76. Acceptability and uptake of HIV-1 self-testing among individuals using pre-exposure prophylaxis in Kenya. Bill & Melinda Gates Foundation: Status and Future for HIV Self-Testing. Seattle, Washington, USA, February 2015.
77. PrEP values and preferences among women and men in Kenya and Uganda. WHO/UNAIDS Scoping Meeting for the Development of Further Recommendations on the Use of PrEP for the Prevention of Sexual Transmission of HIV. Geneva, Switzerland, March 2015.
78. PrEP for HIV prevention: from clinical trials to implementation. UCLA CFAR Grant Rounds. Los Angeles, California, USA, April 2015.
79. PrEP and young women. CDC Division of Global HIV & TB Annual Meeting. Atlanta, Georgia, USA, June 2015.
80. The ECHO study. Microbicide Trials Network Regional Meeting. Cape Town, South Africa. October 2015.
81. Aggregating data for program implementation. PrEP Demonstration Project Meeting. Johannesburg, South Africa. October 2015.
82. What are we testing when we do HIV testing? Planned Parenthood Federation of America National Medical Committee Meeting. Chicago, USA. November 2015.